UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2013.

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____________ to _____________.

Commission File Number: 1-35490

EXPRESS SCRIPTS HOLDING COMPANY

(Exact name of registrant as specified in its charter)

Delaware	45-2884094
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)
One Express Way, St. Louis, MO	63121
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (314) 996-0900

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ý    No  ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  ý  No  ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	ý	Accelerated filer	¨
Non-accelerated filer	¨ (Do not check if a smaller reporting company)	Smaller reporting company	¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ¨    Noý

Common stock outstanding as of September 30, 2013: 805,806,000 Shares

EXPRESS SCRIPTS HOLDING COMPANY

INDEX

Part I	Financial Information
	Item 1.	Financial Statements (unaudited)		3
		a)	Unaudited Consolidated Balance Sheet	3
		b)	Unaudited Consolidated Statement of Operations	4
		c)	Unaudited Consolidated Statement of Comprehensive Income	5
		d)	Unaudited Consolidated Statement of Changes in Stockholders’ Equity	6
		e)	Unaudited Consolidated Statement of Cash Flows	7
		f)	Notes to Unaudited Consolidated Financial Statements	8
	Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations		33
	Item 3.	Quantitative and Qualitative Disclosures About Market Risk		45
	Item 4.	Controls and Procedures		45
Part II	Other Information
	Item 1.	Legal Proceedings		46
	Item 1A.	Risk Factors – (Not Applicable)		—
	Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds		47
	Item 3.	Defaults Upon Senior Securities – (Not Applicable)		—
	Item 4.	Mine Safety Disclosures – (Not Applicable)		—
	Item 5.	Other Information – (Not Applicable)		—
	Item 6.	Exhibits		47
Signatures				48
Index to Exhibits				49

2

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

EXPRESS SCRIPTS HOLDING COMPANY Unaudited Consolidated Balance Sheet
(in millions)	September 30, 2013			December 31, 2012
Assets
Current assets:
Cash and cash equivalents	$	1,722.3		$	2,793.1
Restricted cash and investments	19.2			19.6
Receivables, net	5,112.4			5,425.8
Inventories	1,643.6			1,652.1
Deferred taxes	422.7			400.6
Prepaid expenses and other current assets	179.0			194.3
Current assets of discontinued operations	125.0			271.4
Total current assets	9,224.2			10,756.9
Property and equipment, net	1,629.2			1,632.1
Goodwill	29,306.3			29,320.4
Other intangible assets, net	14,525.9			16,037.9
Other assets	56.6			56.1
Noncurrent assets of discontinued operations	20.8			307.8
Total assets	$	54,763.0		$	58,111.2
Liabilities and Stockholders’ Equity
Current liabilities:
Claims and rebates payable	$	6,459.7		$	7,440.0
Accounts payable	2,573.4			2,898.9
Accrued expenses	1,496.7			1,632.9
Current maturities of long-term debt	631.6			934.9
Current liabilities of discontinued operations	64.8			150.7
Total current liabilities	11,226.2			13,057.4
Long-term debt	13,482.0			14,980.1
Deferred taxes	5,589.0			5,936.5
Other liabilities	746.3			692.9
Noncurrent liabilities of discontinued operations	0.4			48.6
Total liabilities	31,043.9			34,715.5
Commitments and contingencies (Note 10)
Stockholders’ Equity:
Preferred stock, 15.0 shares authorized, $0.01 par value per share; and no shares issued and outstanding	—			—
Common stock, 2,985.0 shares authorized, $0.01 par value; shares issued: 830.7 and 818.1, respectively; shares outstanding: 805.8 and 818.1, respectively	8.3			8.2
Additional paid-in capital	21,820.2			21,289.7
Accumulated other comprehensive income	15.4			18.9
Retained earnings	3,410.9			2,068.2
	25,254.8			23,385.0
Common stock in treasury at cost, 24.9 and zero shares, respectively	(1,552.5		)	—
Total Express Scripts stockholders’ equity	23,702.3			23,385.0
Non-controlling interest	16.8			10.7
Total stockholders’ equity	23,719.1			23,395.7
Total liabilities and stockholders’ equity	$	54,763.0		$	58,111.2

See accompanying Notes to Unaudited Consolidated Financial Statements

3

EXPRESS SCRIPTS HOLDING COMPANY Unaudited Consolidated Statement of Operations
	Three Months Ended  September 30,						Nine Months Ended September 30,
(in millions, except per share data)	2013			2012			2013			2012
Revenues (1)	$	25,915.6		$	26,761.6		$	78,317.4		$	66,349.2
Cost of revenues (1)	23,921.4			24,658.7			72,246.0			61,335.0
Gross profit	1,994.2			2,102.9			6,071.4			5,014.2
Selling, general and administrative	1,118.7			1,282.2			3,348.5			3,127.2
Operating income	875.5			820.7			2,722.9			1,887.0
Other (expense) income:
Equity income from joint venture	6.3			5.1			23.1			9.4
Interest income	25.7			1.4			28.4			6.0
Interest expense and other	(127.4		)	(155.2		)	(470.4		)	(461.6		)
	(95.4		)	(148.7		)	(418.9		)	(446.2		)
Income before income taxes	780.1			672.0			2,304.0			1,440.8
Provision for income taxes	326.5			256.1			896.0			602.5
Net income from continuing operations	453.6			415.9			1,408.0			838.3
Net loss from discontinued operations, net of tax	(15.5		)	(20.0		)	(41.3		)	(19.2		)
Net income	438.1			395.9			1,366.7			819.1
Less: Net income attributable to non-controlling interest	11.4			4.5			24.0			10.3
Net income attributable to Express Scripts	$	426.7		$	391.4		$	1,342.7		$	808.8
Weighted average number of common shares outstanding during the period:
Basic	810.2			812.9			814.7			702.4
Diluted	822.9			829.6			828.0			718.9
Basic earnings per share:
Continuing operations attributable to Express Scripts	$	0.55		$	0.51		$	1.70		$	1.18
Discontinued operations attributable to Express Scripts	(0.02		)	(0.02		)	(0.05		)	(0.03		)
Net earnings attributable to Express Scripts	$	0.53		$	0.48		$	1.65		$	1.15
Diluted earnings per share:
Continuing operations attributable to Express Scripts	$	0.54		$	0.50		$	1.67		$	1.15
Discontinued operations attributable to Express Scripts	(0.02		)	(0.02		)	(0.05		)	(0.03		)
Net earnings attributable to Express Scripts	$	0.52		$	0.47		$	1.62		$	1.13
Amounts attributable to Express Scripts shareholders:
Income from continuing operations, net of tax	$	442.2		$	411.4		$	1,384.0		$	828.0
Discontinued operations, net of tax	(15.5		)	(20.0		)	(41.3		)	(19.2		)
Net income attributable to Express Scripts shareholders	$	426.7		$	391.4		$	1,342.7		$	808.8

1 Includes retail pharmacy co-payments of $2,966.5 and $3,348.9 for the three months ended September 30, 2013 and 2012, respectively, and $9,845.2 and $8,364.6 for the nine months ended September 30, 2013 and 2012, respectively.

See accompanying Notes to Unaudited Consolidated Financial Statements

4

EXPRESS SCRIPTS HOLDING COMPANY Unaudited Consolidated Statement of Comprehensive Income
	Three Months Ended September 30,				Nine Months Ended September 30,
(in millions)	2013		2012		2013			2012
Net income	$	438.1	$	395.9	$	1,366.7		$	819.1
Other comprehensive income (loss):
Foreign currency translation adjustment	2.5		8.5		(3.5		)	(0.4		)
Comprehensive income	440.6		404.4		1,363.2			818.7
Less: Comprehensive income attributable to non-controlling interests	11.4		4.5		24.0			10.3
Comprehensive income attributable to Express Scripts	$	429.2	$	399.9	$	1,339.2		$	808.4

See accompanying Notes to Unaudited Consolidated Financial Statements

5

EXPRESS SCRIPTS HOLDING COMPANY Unaudited Consolidated Statement of Changes in Stockholders’ Equity
	Number of Shares	Amount
(in millions)	Common Stock	Common Stock		Additional Paid-in Capital		Accumulated Other Comprehensive Income			Retained Earnings		Treasury Stock			Non- controlling Interest			Total
Balance at December 31, 2012	818.1	$	8.2	$	21,289.7	$	18.9		$	2,068.2	$	—		$	10.7		$	23,395.7
Net income	—	—		—		—			1,342.7		—			24.0			1,366.7
Other comprehensive loss	—	—		—		(3.5		)	—		—			—			(3.5		)
Treasury stock acquired	—	—		—		—			—		(1,552.5		)	—			(1,552.5		)
Changes in stockholders’ equity related to employee stock plans	12.6	0.1		530.5		—			—		—			—			530.6
Distributions to non-controlling interest	—	—		—		—			—		—			(17.9		)	(17.9		)
Balance at September 30, 2013	830.7	$	8.3	$	21,820.2	$	15.4		$	3,410.9	$	(1,552.5	)	$	16.8		$	23,719.1

See accompanying Notes to Unaudited Consolidated Financial Statements

6

EXPRESS SCRIPTS HOLDING COMPANY Unaudited Consolidated Statement of Cash Flows
	Nine Months Ended September 30,
(in millions)	2013			2012
Cash flows from operating activities:
Net income	$	1,366.7		$	819.1
Net loss from discontinued operations, net of tax	41.3			19.2
Net income from continuing operations	1,408.0			838.3
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	1,824.0			1,270.0
Deferred income taxes	(376.2		)	(338.0		)
Employee stock-based compensation expense	131.2			341.6
Other, net	25.8			43.7
Changes in operating assets and liabilities:
Accounts receivable	194.5			417.1
Inventories	8.6			(358.1		)
Other current and noncurrent assets	37.3			31.5
Claims and rebates payable	(980.3		)	(647.2		)
Accounts payable	(320.5		)	142.7
Other current and noncurrent liabilities	(109.3		)	303.8
Net cash provided by operating activities - continuing operations	1,843.1			2,045.4
Net cash (used in) provided by operating activities - discontinued operations	(20.7		)	9.3
Net cash flows provided by operating activities	1,822.4			2,054.7
Cash flows from investing activities:
Proceeds from sale of business	313.0			31.5
Purchases of property and equipment	(274.6		)	(101.9		)
Acquisitions, net of cash acquired	(14.5		)	(10,326.0		)
Other	(11.8		)	(16.2		)
Net cash provided by (used in) investing activities - continuing operations	12.1			(10,412.6		)
Acquisitions, cash acquired - discontinued operations	—			42.4
Net cash used in investing activities - discontinued operations	(2.1		)	(4.1		)
Net cash provided by (used in) investing activities	10.0			(10,374.3		)
Cash flows from financing activities:
Repayment of long-term debt	(1,773.7		)	(2,710.6		)
Treasury stock acquired	(1,552.5		)	—
Net proceeds from employee stock plans	383.6			276.5
Excess tax benefit relating to employee stock compensation	23.2			30.4
Distributions paid to non-controlling interest	(18.0		)	(5.3		)
Proceeds from long-term debt, net of discounts	—			7,458.9
Repayment of revolving credit line, net	—			(1,000.0		)
Proceeds from accounts receivable financing facility	—			600.0
Repayment of accounts receivable financing facility	—			(600.0		)
Other	15.4			(103.2		)
Net cash (used in) provided by financing activities - continuing operations	(2,922.0		)	3,946.7
Net cash used in financing activities - discontinued operations	—			(1.3		)
Net cash (used in) provided by financing activities	(2,922.0		)	3,945.4
Effect of foreign currency translation adjustment	(4.5		)	2.6
Less: cash decrease (increase) attributable to discontinued operations	23.3			(47.3		)
Net decrease in cash and cash equivalents	(1,070.8		)	(4,418.9		)
Cash and cash equivalents at beginning of period	2,793.1			5,620.1
Cash and cash equivalents at end of period	$	1,722.3		$	1,201.2

See accompanying Notes to Unaudited Consolidated Financial Statements

7

EXPRESS SCRIPTS HOLDING COMPANY

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

Note 1 - Summary of significant accounting policies

On July 20, 2011, Express Scripts, Inc. (“ESI”) entered into a definitive merger agreement (the “Merger Agreement”) with Medco Health Solutions, Inc. (“Medco”), which was amended by Amendment No. 1 thereto on November 7, 2011, providing for the combination of ESI and Medco under a new holding company named Aristotle Holding, Inc. The transactions contemplated by the Merger Agreement (the “Merger”) were consummated on April 2, 2012. Aristotle Holding, Inc. was renamed Express Scripts Holding Company (the “Company” or “Express Scripts”) concurrently with the consummation of the Merger. “We,” “our” or “us” refers to Express Scripts Holding Company and its subsidiaries. For financial reporting and accounting purposes, ESI was the acquirer of Medco. The consolidated financial statements reflect the results of operations and financial position of ESI for the period beginning January 1, 2012 through April 1, 2012. However, references to amounts for periods after the closing of the Merger on April 2, 2012 relate to Express Scripts.

Our significant accounting policies, normally included in financial statements prepared in conformity with generally accepted accounting principles, have been omitted from this Form 10-Q pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Express Scripts believes the disclosures contained in this Form 10-Q are adequate to fairly state the information when read in conjunction with the Notes to the Consolidated Financial Statements included in Express Scripts’ Annual Report on Form 10-K for the year ended December 31, 2012. For a full description of our accounting policies, refer to the Notes to the Consolidated Financial Statements included in Express Scripts’ Annual Report on Form 10-K for the year ended December 31, 2012.

We believe the accompanying unaudited consolidated financial statements reflect all adjustments (consisting of only normal recurring adjustments) necessary to state fairly the unaudited consolidated balance sheet at September 30, 2013, the unaudited consolidated statement of operations and unaudited consolidated statement of comprehensive income for the three and nine months ended September 30, 2013 and 2012, the unaudited consolidated statement of changes in stockholders’ equity for the nine months endedSeptember 30, 2013, and the unaudited consolidated statement of cash flows for the nine months ended September 30, 2013 and 2012. Certain amounts in prior years have been reclassified to conform to the current year presentation. Operating results for the three and nine months ended September 30, 2013 are not necessarily indicative of the results that may be expected for the year ending December 31, 2013.

Discontinued Operations. During 2012, we determined that various businesses acquired in the Merger were no longer core to our future operations and committed to a plan to dispose of these businesses. In the third quarter of 2013, we entered into an agreement for the sale of our acute infusion therapies line of business, which was included within our PBM segment. As a result, these businesses are classified as discontinued operations. In accordance with applicable accounting guidance, the results of operations for these entities are reported as discontinued operations for all periods presented in the accompanying consolidated statement of operations. Additionally, for all periods presented, assets and liabilities of the discontinued operations are segregated in the accompanying consolidated balance sheet and cash flows of our discontinued operations are segregated in our accompanying consolidated statement of cash flows (see Note 4 - Dispositions).

Presentation of Non-Controlling Interest. The accompanying financial statements have been revised to reflect net income attributable to members of our consolidated affiliates. This revision results in a $4.5 million and $10.3 million adjustment from the “Selling, general and administrative” (“SG&A”) line item to the “Net income attributable to non-controlling interest” line item within the consolidated statement of operations for the three and nine months ended September 30, 2012, respectively. This adjustment does not change amounts previously disclosed for the three and nine months ended September 30, 2012 as “Net income attributable to Express Scripts.” This adjustment also affects net income included in cash flows from operating activities in the consolidated statement of cash flows for the nine months endedSeptember 30, 2012. Additionally, within the consolidated statement of cash flows for the nine months endedSeptember 30, 2012, the “Other current and noncurrent liabilities” line item decreased $5.0 million, and a $5.3 million cash outflow is now reflected within the “Distributions paid to non-controlling interest” line item.

New Accounting Guidance. In February 2013, the Financial Accounting Standards Board (“FASB”) issued authoritative guidance containing changes to the presentation of amounts reclassified out of accumulated other comprehensive income. This statement is effective for financial statements issued for annual periods beginning after December 15, 2012. Adoption of the standard impacts the presentation of certain information within the financial statements, but will not impact our financial position, results of operations or cash flows. The Company has not reclassified amounts out of accumulated other comprehensive income; as such, no additional information is presented for the three and nine months ended September 30, 2013 or 2012.

8

In July 2013, the FASB issued authoritative guidance containing changes to the presentation of an unrecognized tax benefit when a loss or credit carryforward exists. This statement is effective for financial statements issued for annual periods beginning after December 15, 2013, with early adoption permitted. Adoption of the standard is not expected to impact our financial position, results of operations, or cash flows.

Note 2 - Fair value measurements

Accounting guidance regarding fair value measurement establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets for identical assets or liabilities; Level 2, defined as inputs other than quoted prices for similar assets and liabilities in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs for which little or no market data exists, therefore requiring an entity to develop its own assumptions.

Financial assets accounted for at fair value on a recurring basis include cash equivalents of $753.9 million and $1,572.3 million, restricted cash and investments of $19.2 million and $19.6 million, and trading securities (included in other assets) of $8.1 million and $15.8 million, at September 30, 2013 and December 31, 2012, respectively. These assets are carried at fair value based on quoted prices in active markets for identical securities (Level 1 inputs). Cash equivalents include investments in AAA-rated money market mutual funds with maturities of less than 90 days.

9

The carrying value of cash and cash equivalents (Level 1), restricted cash and investments (Level 1), accounts receivable, claims and rebates payable, and accounts payable approximated fair values due to the short-term maturities of these instruments. The fair value, which approximates the carrying value, of our bank credit facility (Level 2) was estimated using the current rates offered to us for debt with similar maturities. The carrying values and the fair values of our senior notes are shown, net of unamortized discounts and premiums, in the following table:

	September 30, 2013				December 31, 2012
(in millions)	Carrying Amount		Fair Value		Carrying Amount		Fair Value
March 2008 Senior Notes (acquired)
7.125% senior notes due 2018	$	1,388.3	$	1,435.1	$	1,417.2	$	1,497.3
6.125% senior notes due 2013	—		—		303.3		303.0
	1,388.3		1,435.1		1,720.5		1,800.3
June 2009 Senior Notes
6.250% senior notes due 2014	—		—		998.7		1,076.4
7.250% senior notes due 2019	497.8		610.3		497.6		645.1
	497.8		610.3		1,496.3		1,721.5
September 2010 Senior Notes (acquired)
2.750% senior notes due 2015	507.9		516.2		510.9		522.4
4.125% senior notes due 2020	507.0		519.7		507.6		546.1
	1,014.9		1,035.9		1,018.5		1,068.5
May 2011 Senior Notes
3.125% senior notes due 2016	1,496.7		1,570.1		1,495.8		1,590.2
November 2011 Senior Notes
3.500% senior notes due 2016	1,249.8		1,323.4		1,249.7		1,347.8
4.750% senior notes due 2021	1,241.0		1,336.5		1,240.3		1,425.7
2.750% senior notes due 2014	899.6		919.8		899.4		930.8
6.125% senior notes due 2041	698.4		794.2		698.4		894.6
	4,088.8		4,373.9		4,087.8		4,598.9
February 2012 Senior Notes
2.650% senior notes due 2017	1,490.0		1,548.0		1,487.9		1,559.6
2.100% senior notes due 2015	997.7		1,016.5		996.5		1,023.7
3.900% senior notes due 2022	981.4		1,011.2		980.0		1,073.3
	3,469.1		3,575.7		3,464.4		3,656.6
Total	$	11,955.6	$	12,601.0	$	13,283.3	$	14,436.0

The fair values of our senior notes were estimated based on observable market information (Level 2 inputs). In determining the fair value of liabilities, we took into consideration the risk of nonperformance. Nonperformance risk refers to the risk that the obligation will not be fulfilled and affects the value at which the liability would be transferred to a market participant. This risk did not have a material impact on the fair value of our liabilities.

Note 3 - Changes in business

As a result of the Merger on April 2, 2012, Medco and ESI each became 100% owned subsidiaries of Express Scripts and former Medco and ESI stockholders became owners of Express Scripts stock, which is listed on the Nasdaq. Upon closing of the Merger, former ESI stockholders owned approximately 59% of Express Scripts and former Medco stockholders owned approximately 41% of Express Scripts. Per the terms of the Merger Agreement, upon consummation of the Merger on April 2, 2012, each share of Medco common stock was converted into (i) the right to receive $28.80 in cash, without interest and (ii) 0.81 shares of Express Scripts stock. Holders of Medco stock options, restricted stock units and deferred stock units received replacement awards at an exchange ratio of 1.3474 Express Scripts stock awards for each Medco award owned, which is equal to the sum of (i) 0.81 and (ii) the quotient obtained by dividing (1) $28.80 (the cash component of the Merger

10

consideration) by (2) an amount equal to the average of the closing prices of ESI common stock on the Nasdaq for each of the 15 consecutive trading days ending with the fourth complete trading day prior to the completion of the Merger.

Based on the opening price of Express Scripts’ stock on April 2, 2012, the purchase price was comprised of the following:

(in millions)
Cash paid to Medco stockholders(1)	$	11,309.6
Value of shares of common stock issued to Medco stockholders(2)	17,963.8
Value of stock options issued to holders of Medco stock options(3) (4)	706.1
Value of restricted stock units issued to holders of Medco restricted stock units(3)	174.9
Total consideration	$	30,154.4

(1) Equals Medco outstanding shares multiplied by $28.80 per share.

(2) Equals Medco outstanding shares immediately prior to the Merger multiplied by the exchange ratio of 0.81, multiplied by the Express Scripts opening share price on April 2, 2012 of $56.49.

(3) In accordance with applicable accounting guidance, the fair value of replacement awards attributable to pre-combination service is recorded as part of the consideration transferred in the Merger, while the fair value of replacement awards attributable to post-combination service is recorded separately from the business combination and recognized as compensation cost in the post-acquisition period over the remaining service period.

(4) The fair value of the Company’s equivalent stock options was estimated using the Black-Scholes valuation model utilizing various assumptions. The expected volatility of the Company’s common stock price is a blended rate based on the average historical volatility over the expected term based on daily closing stock prices of ESI and Medco common stock. The expected term of the option is based on Medco historical employee stock option exercise behavior as well as the remaining contractual exercise term.

The following unaudited pro forma information presents a summary of Express Scripts’ combined results of continuing operations for the nine months endedSeptember 30, 2012 as if the Merger and related financing transactions had occurred at January 1, 2012. The following pro forma financial information is not necessarily indicative of the results of operations as it would have been had the transactions been effected on the assumed date, nor is it necessarily an indication of trends in future results for a number of reasons, including, but not limited to, differences between the assumptions used to prepare the pro forma information, basic shares outstanding and dilutive equivalents, cost savings from operating efficiencies, potential synergies and the impact of incremental costs incurred in integrating the businesses:

(in millions, except per share data)	Nine months ended September 30, 2012
Total revenues	$	82,079.3
Net income attributable to Express Scripts	688.7
Basic earnings per share from continuing operations	0.98
Diluted earnings per share from continuing operations	0.96

Pro forma net income for the nine months endedSeptember 30, 2012 includes total non-recurring amounts of $922.5 million related to severance payments, accelerated stock-based compensation and transaction and integration costs incurred in connection with the Merger.

The Merger has been accounted for under the acquisition method of accounting with ESI treated as the acquirer for accounting purposes. The purchase price has been allocated based on the estimated fair value of net assets acquired and liabilities assumed at the date of the acquisition.

During the quarter ended March 31, 2013, the Company made refinements to its preliminary allocation of purchase price related to accrued liabilities due to the finalization of assumptions utilized to value the liabilities acquired. These adjustments had the effect of increasing current assets and other noncurrent liabilities and decreasing goodwill, deferred tax liabilities and current liabilities.

11

Express Scripts finalized the purchase price allocation and push down accounting as of March 31, 2013. The following table summarizes Express Scripts’ estimates of the fair values of the assets acquired and liabilities assumed in the Merger:

(in millions)	Amounts Recognized as of  Acquisition Date
Current assets	$	6,934.9
Property and equipment	1,390.6
Goodwill	23,965.6
Acquired intangible assets	16,216.7
Other noncurrent assets	48.3
Current liabilities	(8,966.4		)
Long-term debt	(3,008.3		)
Deferred income taxes	(5,875.2		)
Other noncurrent liabilities	(551.8		)
Total	$	30,154.4

A portion of the excess of purchase price over tangible net assets acquired has been allocated to intangible assets consisting of customer contracts in the amount of $15,935.0 million with an estimated weighted average amortization period of 16 years. Additional intangible assets consist of trade names in the amount of $273.0 million with an estimated weighted average amortization period of 10 years and miscellaneous intangible assets of $8.7 million with an estimated weighted average amortization period of 5 years. The acquired intangible assets have been valued using an income approach and are being amortized on a basis that approximates the pattern of benefit.

The excess of purchase price over tangible net assets and identified intangible assets acquired has been allocated to goodwill in the amount of $23,965.6 million. The majority of the goodwill recognized as part of the Merger is reported under our Pharmacy Benefit Management (“PBM”) segment and reflects our expected synergies from combining operations, such as improved economies of scale and cost savings. Goodwill recognized is not expected to be deductible for income tax purposes and is not amortized.

Note 4 - Dispositions

During 2013, we sold or impaired various businesses that were no longer core to our future operations. Below is a summary of charges associated with these businesses and the impact to our consolidated statement of operations:

	Three Months Ended September 30, 2013					Nine Months Ended September 30, 2013
(in millions)	Gain recorded		Goodwill Impairment			Gain recorded		Goodwill Impairment
Disposed UBC operations
Technology solutions and publications for biopharmaceutical companies	$	—	$	—		$	18.3	$	—
Health economics, outcomes research, data analytics and market access services	11.4		—			11.4		—
Specialty services for pre-market trials	22.1		—			22.1		—
Acute infusion therapies line of business	—		(32.9		)	—		(32.9		)
Recorded in net loss from discontinued operations, net of tax	33.5		(32.9		)	51.8		(32.9		)
CYC(1)	—		—			3.5		—
Recorded in selling, general and administrative	—		—			3.5		—
Total disposition charges	$	33.5	$	(32.9	)	$	55.3	$	(32.9	)

(1) Reflects the settlement of certain working capital balances in 2013.

12

Sale of CYC. In the third quarter of 2012, we completed the sale of our ConnectYourCare (“CYC”) line of business, which was included within our Other Business Operations segment. During the first quarter of 2013, certain working capital balances were settled, resulting in a $3.5 million gain. The gain is included in the SG&A line item in the accompanying unaudited consolidated statement of operations for the nine months ended September 30, 2013.

Sale of Liberty. In the fourth quarter of 2012, we completed the sale of our PolyMedica Corporation (“Liberty”) line of business, which was included within our Other Business Operations segment. Liberty sells diabetes testing supplies and is located in Port St. Lucie, Florida. Immediately following the time Liberty became independently owned and operated, Express Scripts and Liberty entered into an arms-length agreement whereby Express Scripts will work as a back-end pharmacy supplier for portions of the Liberty business for a minimum of two years. As such, the Company expects continued revenue (and resulting cash flows) associated with Liberty, which precludes classification of this business as a discontinued operation.

Sale of EAV. In the fourth quarter of 2012, we completed the sale of our Europa Apotheek Venlo B.V. (“EAV”) line of business, which primarily provided home delivery pharmacy services in Germany. Prior to being classified as a discontinued operation, EAV was included within our Other Business Operations segment.

Discontinued Operations of Europe and portions of UBC. During the fourth quarter of 2012, we determined that certain portions of the business within United BioSource LLC (“UBC”), which is located in Blue Bell, Pennsylvania, and our operations in Europe (“European Operations”), which were included within our Other Business Operations segment, were not core to our future operations and committed to a plan to dispose of these businesses. As a result, these businesses were classified as discontinued operations as of December 31, 2012. UBC is a global medical and scientific affairs organization that partners with life science companies to develop and commercialize their products. The portions of UBC that were held for sale include specialty services for pre-market trials; health economics, outcomes research, data analytics and market access services; and technology solutions and publications for biopharmaceutical companies. Our European Operations primarily consist of clinical and specialty pharmacy management services. It is expected that our European Operations will be disposed of in the first half of 2014.

On June 7, 2013, we completed the sale of the portion of our UBC business which primarily provided technology solutions and publications for biopharmaceutical companies. During the second quarter of 2013, we recognized a gain on the sale of this business which totaled $18.3 million. The gain on this portion of UBC is included in the “Net loss from discontinued operations, net of tax” line item in the accompanying consolidated statement of operations for the nine months endedSeptember 30, 2013.

On July 1, 2013, we completed the sale of the portion of our UBC business related to providing health economics, outcomes research, data analytics and market access services. During the third quarter of 2013, we recognized a gain on the sale of this business which totaled $11.4 million. On August 15, 2013, we completed the sale of the portion of our UBC business related to specialty services for pre-market trials. During the third quarter of 2013, we recognized a gain on the sale of this business which totaled $22.1 million. The gains on these two sales are included in the “Net loss from discontinued operations, net of tax” line item in the accompanying consolidated statement of operations for the three and nine months ended September 30, 2013. These three sales represent the remaining portions of UBC classified as discontinued operations.

Discontinued operations of acute infusion therapies line of business. In the third quarter of 2013, we entered into an agreement for the sale of our acute infusion therapies line of business, which was included within our PBM segment. As a result, this business is classified as discontinued operations. The sale of this business is expected to close during the fourth quarter of 2013.

In connection with entering into an agreement for the sale of the business, an impairment in the value of the related goodwill was identified. The impairment charge, which totaled $32.9 million, was recorded during the third quarter of 2013 and reflects goodwill impairment and the subsequent write-down to fair market value. The fair value was determined utilizing the contracted sales price of the business (Level 2). The impairment charge is included in the “Net loss from discontinued operations, net of tax” line item in the accompanying unaudited consolidated statement of operations. Additional costs and charges may be incurred during future periods; however, they are not expected to be material.

13

The results of the disposed portions of UBC, as defined above, our European Operations and our acute infusion therapies line of business are reported as discontinued operations for all periods presented in the accompanying unaudited consolidated statements of operations in accordance with applicable accounting guidance. As such, results of operations for the three and nine months ended September 30, 2012 have been adjusted to reflect these operations as discontinued. As the discontinued operations were acquired through the Merger, results of operations for the three months ended March 31, 2012 do not include these operations in our accompanying unaudited consolidated statement of operations. Additionally, for all periods presented, cash flows of our discontinued operations are segregated in our accompanying unaudited consolidated statements of cash flows. Finally, assets and liabilities of these businesses held were segregated in our accompanying unaudited consolidated balance sheet as of September 30, 2013 and consolidated balance sheet as of December 31, 2012. The major components of the assets and liabilities of these discontinued operations are as follows:

(in millions)	September 30, 2013		December 31, 2012
Current assets	$	125.0	$	271.4
Goodwill	6.5		127.9
Other intangible assets, net	—		157.4
Other assets	14.3		22.5
Total assets	$	145.8	$	579.2
Current liabilities	$	64.8	$	150.7
Deferred taxes	—		44.9
Other liabilities	0.4		3.7
Total liabilities	$	65.2	$	199.3

Certain information with respect to the discontinued operations, as defined above, for the three and nine months ended September 30, 2013 and 2012 is summarized as follows:

	Three Months Ended September 30,						Nine Months Ended September 30,
(in millions)	2013			2012			2013			2012
Revenues	$	136.2		$	237.8		$	474.1		$	475.3
Operating loss	(1.8		)	(17.7		)	(15.9		)	(18.0		)
Income tax expense (benefit) from discontinued operations	13.7			(1.6		)	25.4			0.3
Net loss from discontinued operations, net of tax	(15.5		)	(20.0		)	(41.3		)	(19.2		)

14

Note 5 - Goodwill and other intangible assets

The following is a summary of our goodwill and other intangible assets for our two reportable segments: PBM and Other Business Operations.

	September 30, 2013							December 31, 2012(1)
(in millions)	Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount
Goodwill
PBM(2)	$	29,316.3	$	(107.4	)	$	29,208.9	$	29,330.4	$	(107.4	)	$	29,223.0
Other Business Operations	97.4		—			97.4		97.4		—			97.4
	$	29,413.7	$	(107.4	)	$	29,306.3	$	29,427.8	$	(107.4	)	$	29,320.4
Other intangible assets
PBM
Customer contracts	$	17,686.9	$	(3,516.0	)	$	14,170.9	$	17,672.7	$	(2,038.3	)	$	15,634.4
Trade names	226.6		(33.5		)	193.1		226.6		(16.7		)	209.9
Miscellaneous(3)	111.6		(42.5		)	69.1		121.6		(34.9		)	86.7
	18,025.1		(3,592.0		)	14,433.1		18,020.9		(2,089.9		)	15,931.0
Other Business Operations
Customer relationships(4)	127.3		(65.0		)	62.3		138.5		(63.2		)	75.3
Trade names	35.7		(5.2		)	30.5		34.7		(3.1		)	31.6
	163.0		(70.2		)	92.8		173.2		(66.3		)	106.9
Total other intangible assets	$	18,188.1	$	(3,662.2	)	$	14,525.9	$	18,194.1	$	(2,156.2	)	$	16,037.9

(1) Goodwill associated with the PBM now excludes discontinued operations of our acute infusion therapies line of business.

(2) Goodwill has been reduced by $12.7 million due to finalization of the purchase price allocation during the first quarter of 2013.

(3) Balances as of September 30, 2013 include a decrease of $10.0 million to both gross miscellaneous assets and related accumulated amortization following the write-off of deferred financing fees related to the early repayment and the redemption of senior notes. See Note 7 - Financing for additional information.

(4) As of September 30, 2013, gross customer relationships and related accumulated amortization reflect a decrease of $11.2 million. These balances reflect amounts previously written off and have no net impact on the net other intangible assets balance.

As discussed in Note 4 - Dispositions, our acute infusion therapies line of business was classified as a discontinued operation during the third quarter of 2013. In connection with entering into an agreement for the sale of the business, an impairment in the value of the related goodwill was identified. The impairment charge, which totaled $32.9 million, was recorded during the third quarter of 2013. The impairment charge is included in the “Net loss from discontinued operations, net of tax” line item in the accompanying unaudited consolidated statement of operations.

Our PBM gross customer contract balance as of September 30, 2013 includes an increase of $14.5 million. This new intangible asset has a useful life of 10 years and is the result of our asset acquisition of the SmartD Medicare Prescription Drug Plan (“PDP”) on September 1, 2013. The asset acquisition added 87,000 covered Medicare lives to our existing PDP offering.

The aggregate amount of amortization expense of other intangible assets for our continuing operations was $510.0 million and $527.1 million for the three months ended September 30, 2013 and 2012, respectively, and $1,527.5 million and $1,104.9 million for the nine months ended September 30, 2013 and 2012, respectively. In accordance with applicable accounting guidance, amortization for customer contracts related to our agreement to provide PBM services to members of the affiliated health plans of WellPoint has been included as an offset to revenues in the amount of $28.5 million for the three months ended September 30, 2013 and 2012 and $85.5 million for the nine months ended September 30, 2013 and 2012. The aggregate amount of amortization expense of other intangible assets for our continuing operations is expected to be approximately $2,040.0 million for 2013, $1,767.8 million for 2014, $1,747.7 million for 2015, $1,739.9 million for 2016 and $1,322.4 million for 2017. The weighted average amortization period of intangible assets subject to amortization is 16 years, and by major intangible asset class is 5 to 20 years for customer-related intangible assets and 2 to 30 years for other intangible assets.

15

A summary of the change in the net carrying value of goodwill by business segment is shown in the following table:

(in millions)	PBM			Other Business Operations		Total
Balance at December 31, 2012(1)	$	29,223.0		$	97.4	$	29,320.4
Purchase price allocation adjustment(2)	(12.7		)	—		(12.7		)
Foreign currency translation and other	(1.4		)	—		(1.4		)
Balance at September 30, 2013	$	29,208.9		$	97.4	$	29,306.3

(1) Revised to exclude discontinued operations of our acute infusion therapies line of business.

(2) Goodwill associated with the Merger has been adjusted due to finalization of the purchase price allocation during the first quarter of 2013.

Note 6 - Earnings per share

Basic earnings per share (“EPS”) is computed using the weighted average number of common shares outstanding during the period. Diluted EPS is computed in the same manner as basic EPS but adds the number of additional common shares that would have been outstanding for the period if the dilutive potential common shares had been issued. All shares are calculated under the “treasury stock” method. The following is the reconciliation between the number of weighted average shares used in the basic and diluted EPS calculations for all periods:

	Three Months Ended September 30,		Nine Months Ended September 30,
(in millions)	2013(1)	2012	2013(1)	2012
Weighted average number of common shares outstanding during the period—Basic	810.2	812.9	814.7	702.4
Dilutive common stock equivalents:
Outstanding stock options, “stock-settled” stock appreciation rights, restricted stock units and executive deferred compensation units	12.7	16.7	13.3	16.5
Weighted average number of common shares outstanding during the period—Diluted(2)	822.9	829.6	828.0	718.9

(1) The decrease in the weighted average number of common shares outstanding for the three months ended September 30, 2013 used for both Basic and Diluted EPS resulted primarily from the repurchase of 11.6 million of treasury shares. The increase in the weighted average number of common shares outstanding for the nine months ended September 30, 2013 used for both Basic and Diluted EPS resulted primarily from the issuance of 318.0 million shares in connection with the Merger, partially offset by the repurchase of 24.9 million of treasury shares for the nine months ended September 30, 2013.

(2) Excludes awards of 3.0 million and 3.5 million for the three months ended September 30, 2013 and 2012, respectively, and 4.1 million and 5.9 million for the nine months ended September 30, 2013 and 2012, respectively. These were excluded because their effect was anti-dilutive.

16

Note 7 - Financing

The Company’s debt, net of unamortized discounts and premiums, consists of:

(in millions)	September 30, 2013		December 31, 2012
Long-term debt:
March 2008 Senior Notes (acquired)
7.125% senior notes due 2018	$	1,388.3	$	1,417.2
6.125% senior notes due 2013	—		303.3
	1,388.3		1,720.5
June 2009 Senior Notes
6.250% senior notes due 2014	—		998.7
7.250% senior notes due 2019	497.8		497.6
	497.8		1,496.3
September 2010 Senior Notes (acquired)
2.750% senior notes due 2015	507.9		510.9
4.125% senior notes due 2020	507.0		507.6
	1,014.9		1,018.5
May 2011 Senior Notes
3.125% senior notes due 2016	1,496.7		1,495.8
November 2011 Senior Notes
3.500% senior notes due 2016	1,249.8		1,249.7
4.750% senior notes due 2021	1,241.0		1,240.3
2.750% senior notes due 2014	899.6		899.4
6.125% senior notes due 2041	698.4		698.4
	4,088.8		4,087.8
February 2012 Senior Notes
2.650% senior notes due 2017	1,490.0		1,487.9
2.100% senior notes due 2015	997.7		996.5
3.900% senior notes due 2022	981.4		980.0
	3,469.1		3,464.4
Term facility due August 29, 2016 with an average interest rate of 1.94% at September 30, 2013 and 1.96% at December 31, 2012	2,157.9		2,631.6
Other	0.1		0.1
Total debt	14,113.6		15,915.0
Less: Current maturities of long-term debt	631.6		934.9
Total long-term debt	$	13,482.0	$	14,980.1

BANK CREDIT FACILITIES

On August 29, 2011, ESI entered into a credit agreement (the “credit agreement”) with a commercial bank syndicate providing for a five-year $4.0 billion term loan facility (the “term facility”) and a $1.5 billion revolving loan facility (the “revolving facility”). The term facility was used to pay a portion of the cash consideration in connection with the Merger (as discussed in Note 3 - Changes in business), to repay existing indebtedness and to pay related fees and expenses. Upon consummation of the Merger, Express Scripts assumed the obligations of ESI and became the borrower under the credit agreement and revolving facility. Subsequent to consummation of the Merger on April 2, 2012, the revolving facility has been available for general corporate purposes. The term facility and the revolving facility both mature on August 29, 2016. As of September 30, 2013, no balance was outstanding under the revolving facility. The Company makes quarterly principal payments on the term facility. As of September 30, 2013, $631.6 million of this facility is considered current maturities of long-term debt.

17

The credit agreement requires interest to be paid at the LIBOR or adjusted base rate options, plus a margin. The margin over LIBOR ranges from 1.25% to 1.75% for the term facility and 1.10% to 1.55% for the revolving facility, and the margin over the base rate options ranges from 0.25% to 0.75% for the term facility and 0.10% to 0.55% for the revolving facility, depending on our consolidated leverage ratio. Under the credit agreement, we are required to pay commitment fees on the unused portion of the $1.5 billion revolving facility. The commitment fee ranges from 0.15% to 0.20% depending on our consolidated leverage ratio.

SENIOR NOTES

On March 29, 2013, the Company redeemed ESI’s $1.0 billion aggregate principal amount of 6.250% senior notes due 2014. These notes were redeemable at a redemption price equal to the greater of (i) 100% of the aggregate principal amount of the notes being redeemed, plus accrued and unpaid interest; or (ii) the sum of the present values of the remaining scheduled payments of principal and interest on the notes being redeemed, not including unpaid interest accrued to the redemption date, discounted to the redemption date on a semiannual basis at the treasury rate plus 50 basis points with respect to the notes being redeemed, plus unpaid interest of the notes being redeemed accrued to the redemption date. Total cash payments related to the redemption of these notes were $1.1 billion, which included $68.5 million of redemption costs and write-off of deferred financing fees which are reflected within the “Interest expense and other” line item of the unaudited consolidated statement of operations for the nine months ended September 30, 2013.

On March 18, 2013, $300.0 million aggregate principal amount of 6.125% senior notes due 2013, issued by Medco, matured and were redeemed.

COVENANTS

Our bank financing arrangements contain covenants that restrict our ability to incur additional indebtedness, create or permit liens on assets and engage in mergers or consolidations. The covenants also include minimum interest coverage ratios and maximum leverage ratios. The 7.125% senior notes due 2018 issued by Medco are also subject to an interest rate adjustment in the event of a downgrade in the ratings to below investment grade. At September 30, 2013, we believe we were in compliance in all material respects with all covenants associated with our debt instruments (including the credit agreement and our senior notes).

Note 8 - Common stock

On March 6, 2013, the Board of Directors of Express Scripts approved a new share repurchase program (the “2013 Share Repurchase Program”), authorizing the repurchase of up to 75.0 million shares (as adjusted for any subsequent stock split, stock dividend or similar transaction) of the Company’s common stock. There is no limit on the duration of the 2013 Share Repurchase Program.

During the three and nine months ended September 30, 2013, we repurchased 11.6 million and 24.9 million shares for $751.5 million and $1,552.5 million, respectively. Repurchases during the second quarter included 1.2 million shares of common stock for an aggregate purchase price of $68.4 million that were held on behalf of participants who acquired such shares upon the consummation of the Merger as a result of conversion of Medco shares previously held in Medco’s 401(k) plan. As previously announced, the Express Scripts 401(k) Plan no longer offers an investment fund option consisting solely of shares of Express Scripts common stock, and previously held shares were to be sold on or about the first anniversary of the Merger. This repurchase was not considered part of the 2013 Share Repurchase Program. The remaining shares repurchased throughout 2013 were purchased as part of the 2013 Share Repurchase Program. As of September 30, 2013, there were 51.3 million shares remaining under the 2013 Share Repurchase Program. Additional share repurchases, if any, will be made in such amounts and at such times as the Company deems appropriate based upon prevailing market and business conditions and other factors. Current year repurchases were funded through internally generated cash.

18

Note 9 - Stock-based compensation plans

In March 2011, ESI’s Board of Directors adopted the ESI 2011 Long-Term Incentive Plan (the “2011 LTIP”), which provides for the grant of various equity awards with various terms to our officers, directors and key employees selected by the Compensation Committee of the Board of Directors. The 2011 LTIP was approved by ESI’s stockholders in May 2011 and became effective June 1, 2011. Upon consummation of the Merger, the Company assumed sponsorship of the 2011 LTIP. Under the 2011 LTIP, we may issue stock options, stock-settled stock appreciation rights (“SSRs”), restricted stock units, restricted stock awards, performance share awards and other types of awards. Subsequent to the effective date of the 2011 LTIP, no additional awards have been or will be granted under the 2000 Long-Term Incentive Plan (“2000 LTIP”), which provided for the grant of various equity awards with various terms to our officers, directors and key employees selected by the Compensation Committee.

Effective upon the closing of the Merger, the Company assumed sponsorship of the Medco Health Solutions, Inc. 2002 Stock Incentive Plan (the “2002 Stock Incentive Plan”), allowing Express Scripts to issue awards under this plan. Under the 2002 Stock Incentive Plan, Medco granted, and, following the Merger, Express Scripts has granted and may continue to grant, stock options, restricted stock units and other types of awards to officers, employees and directors.

Awards granted under the 2000 LTIP, the 2011 LTIP and the 2002 Stock Incentive Plan are subject to accelerated vesting under certain specified circumstances resulting from a change in control and termination. The maximum term of stock options, SSRs, restricted stock and performance shares granted under the 2000 LTIP, the 2011 LTIP and the 2002 Stock Incentive Plan is 10 years.

Under our stock-based compensation plans, we have issued stock options, SSRs, restricted stock awards, restricted stock units and performance share awards. Subsequent to the Merger, all awards are settled by issuance of new shares. During the nine months ended September 30, 2013, we granted 3.3 million stock options with a weighted average fair market value of $17.17. The SSRs and stock options granted under the 2000 LTIP, 2011 LTIP and 2002 Stock Incentive Plan have three-year graded vesting. Due to the nature of the awards, we use the same valuation methods and accounting treatments for SSRs and stock options.

The fair value of options and SSRs granted is estimated on the date of grant using a Black-Scholes multiple option-pricing model with the following weighted average assumptions:

	Three Months Ended September 30,		Nine Months Ended September 30,
	2013	2012	2013	2012
Expected life of option	4-5 years	3-5 years	4-5 years	2-5 years
Risk-free interest rate	1.3%-1.7%	0.3%-0.6%	0.6%-1.7%	0.3%-0.9%
Expected volatility of stock	28%-35%	29%-38%	28%-37%	29%-38%
Expected dividend yield	None	None	None	None

The Black-Scholes model requires subjective assumptions, including future stock price volatility and expected time to exercise, which greatly affect the calculated values. The expected term and forfeiture rate of options granted is derived from historical data on employee exercises and post-vesting employment termination behavior as well as expected behavior on outstanding options. The risk-free rate is based on the U.S. Treasury rates in effect during the corresponding period of grant. The expected volatility is based on the historical volatility of our stock price. These factors could change in the future, which would affect the stock-based compensation expense in future periods.

During the nine months ended September 30, 2013, we granted to certain officers and employees approximately 1.1 million restricted stock units and performance shares with a weighted average fair market value of $58.28. Restricted stock units and performance shares granted under the 2000 LTIP, 2011 LTIP and 2002 Stock Incentive Plan vest over three years. Restricted stock units granted under the 2011 LTIP and the 2002 Stock Incentive Plan subsequent to the Merger vest on a graded schedule. Performance shares, as well as Medco’s restricted stock units granted under the 2002 Stock Incentive Plan prior to the Merger, cliff vest at the end of the vesting period. The number of performance shares that ultimately vest is dependent upon achieving specific performance targets. Prior to vesting, performance shares are subject to forfeiture without consideration upon termination of employment under certain circumstances. The original grant of performance shares is subject to a multiplier of up to 2.5 based on the achievement of certain performance metrics. During the nine months ended September 30, 2013, approximately 0.1 million additional performance shares were settled, and common shares were issued to certain officers for achieving certain performance metrics.

19

We recognized stock-based compensation expense of $44.2 million and $95.3 million in the three months ended September 30,2013 and 2012, respectively, and $131.2 million and $341.6 million in the nine months ended September 30, 2013 and 2012, respectively. The decrease in pre-tax compensation expense for the 2013 periods resulted from awards converted in connection with the Merger in the second quarter of 2012. Unamortized stock-based compensation as of September 30, 2013 was $64.9 million for stock options and SSRs and $75.1 million for restricted stock units and performance shares.

Note 10 - Commitments and contingencies

In the ordinary course of business there have arisen various legal proceedings, investigations, recoupment demands or claims now pending against us or our subsidiaries. In accordance with applicable accounting guidance, we record accruals for certain of our outstanding legal proceedings, investigations or claims when it is probable that a liability will be incurred and the amount of loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings, investigations or claims that could affect the amount of any accrual, as well as any developments that would make a loss contingency both probable and reasonably estimable. We disclose the amount of the accrual if the financial statements would be otherwise misleading, which was not the case for any such accruals for the nine months ended September 30,2013 or 2012.

We record self-insurance accruals based upon estimates of the aggregate liability of claim costs in excess of our insurance coverage. Accruals are estimated using certain actuarial assumptions followed in the insurance industry and our historical experience. The majority of these claims are legal claims and our liability estimate is primarily related to the cost to defend these claims. We do not accrue for settlements, judgments, monetary fines or penalties until such amounts are probable and estimable. Under authoritative accounting guidance, if the range of probable loss is broad, the liability accrued should be based on the lower end of the range.

When a loss contingency is not both probable and estimable, we do not establish an accrued liability. However, if the loss (or an additional loss in excess of the accrual) is at least a reasonable possibility and material, then we disclose an estimate of the possible loss or range of loss, if such estimate can be made, or disclose that an estimate cannot be made.

The assessments of whether a loss is probable or a reasonable possibility, and whether the loss or a range of loss is estimable, often involve a series of complex judgments about future events. We are often unable to estimate a range of reasonably possible losses, particularly where (i) the damages sought are substantial or indeterminate, (ii) the proceedings are in the early stages, or (iii) the matters involve novel or unsettled legal theories or a large number of parties. In such cases, there is considerable uncertainty regarding the timing or ultimate resolution of such matters, including a possible eventual loss, fine, penalty or business impact. Accordingly, for many proceedings, we are currently unable to estimate the loss or a range of possible loss. For a limited number of proceedings, we may be able to reasonably estimate the possible range of loss in excess of any accruals. However, we believe that such matters, individually and in the aggregate, when finally resolved, are not reasonably likely to have a material adverse effect on our consolidated cash flow or financial condition. We also believe that any amount that could be reasonably estimated in excess of accruals, if any, for such proceedings is not material. However, an adverse resolution of one or more of such matters could have a material adverse effect on our results of operations in a particular quarter or fiscal year.

While we believe our services and business practices are in compliance with applicable laws, rules and regulations in all material respects, we cannot predict the outcome of these claims at this time. An unfavorable outcome in one or more of these matters could result in the imposition of judgments, monetary fines or penalties, or injunctive or administrative remedies. We can give no assurance that such judgments, fines and remedies, and future costs associated with any such matters, would not have a material adverse effect on our financial condition, our consolidated results of operations or our consolidated cash flows.

Note 11 - Segment information

We report segments on the basis of services offered and have determined we have two reportable segments: PBM and Other Business Operations.

Operating income is the measure used by our chief operating decision maker to assess the performance of each of our operating segments. The following table presents information about our reportable segments, including a reconciliation of operating income from continuing operations to income before income taxes from continuing operations, for the three and nine months ended September 30, 2013 and 2012.

20

During 2012 and 2013, we determined that various businesses acquired in the Merger were no longer core to our future operations and committed to a plan to dispose of these businesses. In accordance with applicable accounting guidance, the results of operations for these entities are reported as discontinued operations for all periods presented in the accompanying information.

(in millions)	PBM		Other Business Operations			Total
For the three months ended September 30, 2013
Product revenues:
Network revenues(1)	$	15,387.3	$	—		$	15,387.3
Home delivery and specialty revenues(2)	9,705.7		—			9,705.7
Other revenues	—		533.7			533.7
Service revenues	237.7		51.2			288.9
Total revenues	25,330.7		584.9			25,915.6
Depreciation and amortization expense	607.3		7.0			614.3
Operating income	863.3		12.2			875.5
Equity income from joint venture						6.3
Interest income						25.7
Interest expense and other						(127.4		)
Income before income taxes						780.1
Capital expenditures	76.4		3.2			79.6
For the three months ended September 30, 2012
Product revenues:
Network revenues(1)	$	16,341.9	$	—		$	16,341.9
Home delivery and specialty revenues(2)	9,531.8		—			9,531.8
Other revenues	—		601.3			601.3
Service revenues	233.7		52.9			286.6
Total revenues	26,107.4		654.2			26,761.6
Depreciation and amortization expense	599.4		11.1			610.5
Operating income (loss)	841.6		(20.9		)	820.7
Equity income from joint venture						5.1
Interest income						1.4
Interest expense and other						(155.2		)
Income before income taxes						672.0
Capital expenditures	34.3		3.7			38.0
For the nine months ended September 30, 2013
Product revenues:
Network revenues(1)	$	47,758.8	$	—		$	47,758.8
Home delivery and specialty revenues(2)	28,164.1		—			28,164.1
Other revenues	—		1,489.0			1,489.0
Service revenues	750.5		155.0			905.5
Total revenues	76,673.4		1,644.0			78,317.4
Depreciation and amortization expense	1,803.4		20.6			1,824.0
Operating income	2,686.3		36.6			2,722.9
Equity income from joint venture						23.1
Interest income						28.4
Interest expense and other						(470.4		)
Income before income taxes						2,304.0
Capital expenditures	269.0		5.6			274.6

21

(in millions)	PBM		Other Business Operations			Total
For the nine months ended September 30, 2012
Product revenues:
Network revenues(1)	$	40,860.5	$	—		$	40,860.5
Home delivery and specialty revenues(2)	23,254.5		—			23,254.5
Other revenues	—		1,558.7			1,558.7
Service revenues	563.6		111.9			675.5
Total revenues	64,678.6		1,670.6			66,349.2
Depreciation and amortization expense	1,244.5		25.5			1,270.0
Operating income (loss)	1,910.4		(23.4		)	1,887.0
Equity income from joint venture						9.4
Interest income						6.0
Interest expense and other						(461.6		)
Income before income taxes						1,440.8
Capital expenditures	93.7		8.2			101.9

(1) Includes retail pharmacy co-payments of $2,966.5 million and $3,348.9 million for the three months ended September 30, 2013 and 2012, respectively, and $9,845.2 million and $8,364.6 million for the nine months ended September 30, 2013 and 2012, respectively.

(2) Includes home delivery, specialty and other including: (a) drugs distributed through patient assistance programs and (b) drugs we distribute to other PBMs’ clients under limited distribution contracts with pharmaceutical manufacturers, and (c) FreedomFP claims.

The following table presents balance sheet information about our reportable segments, including the discontinued operations of our businesses within UBC that were sold, our European Operations, and our acute infusion therapies line of business:

(in millions)	PBM		Other Business Operations		Discontinued Operations		Total
As of September 30, 2013
Total assets	$	53,751.2	$	866.0	$	145.8	$	54,763.0
Investment in equity method investees	$	29.5	$	—	$	—	$	29.5
As of December 31, 2012
Total assets	$	54,510.8	$	3,021.2	$	579.2	$	58,111.2
Investment in equity method investees	$	11.9	$	—	$	—	$	11.9

PBM product revenues consist of revenues from the sale of prescription drugs by retail pharmacies in our retail pharmacy networks, revenues from the dispensing of prescription drugs from our home delivery pharmacies and distribution of certain fertility and specialty drugs. Other Business Operations product revenues consist of specialty distribution activities and development of scientific evidence to guide the safe, effective and affordable use of medicines. PBM service revenues include administrative fees associated with the administration of retail pharmacy networks contracted by certain clients, informed decision counseling services and specialty distribution services. Other Business Operations service revenues include revenues related to data analytics and research associated with our UBC business as well as from healthcare card administration from the period January 1, 2012 through September 14, 2012, the date of disposal of CYC.

The top five clients in the aggregate represent 37.5% and 38.7% of our consolidated revenue for the three and ninemonths ended September 30, 2013, respectively. None of these clients on an individual basis exceed 12.6% of consolidated revenues for the three and nine months ended September 30, 2013.

22

Revenues earned by our continuing operations international businesses totaled $41.1 million and $31.8 million for the three months ended September 30, 2013 and 2012, respectively, and $76.7 million and $71.6 million for the nine months ended September 30, 2013 and 2012, respectively. All other continuing operations revenues were earned in the United States. Long-lived assets of our continuing operations international businesses (consisting primarily of fixed assets) totaled $49.2 million and $32.6 million as of September 30, 2013 and December 31, 2012, respectively. All other continuing operations long-lived assets are domiciled in the United States.

Note 12 - Condensed consolidating financial information

The senior notes issued by the Company, ESI and Medco are jointly and severally and fully and unconditionally (subject to certain customary release provisions, including sale, exchange, transfer or liquidation of the guarantor subsidiary) guaranteed by our 100% owned domestic subsidiaries, other than certain regulated subsidiaries, and, with respect to notes issued by ESI and Medco, by us. The following condensed consolidating financial information has been prepared in accordance with the requirements for presentation of such information. The condensed consolidating financial information presented below is not indicative of what the financial position, results of operations, or cash flows would have been had each of the entities operated as an independent company during the period for various reasons, including, but not limited to, intercompany transactions and integration of systems.

In December 2012 we sold both our Liberty and EAV subsidiaries. In addition, during the fourth quarter of 2012, we determined that our European Operations and portions of UBC met the criteria of discontinued operations. In June 2013 we sold the portion of our UBC business which primarily provided technology solutions and publications to biopharmaceutical companies, and in the third quarter of 2013 we sold the remaining portions of our UBC business that were classified as discontinued. In the third quarter of 2013, we entered into an agreement for the sale of our acute infusion therapies line of business and classified the business as a discontinued operation. Consequently, the operations of EAV, our European Operations, and the portions of UBC operations that were sold are included as discontinued operations of the non-guarantors as of and for the three and nine months ended September 30, 2013 and 2012 (through their respective dates of sale, as applicable), and as of December 31, 2012. The operations of our acute infusion therapies line of business are included as discontinued operations of the guarantors as of and for the three and nine months ended September 30, 2013 and 2012, and as of December 31, 2012. Results for the three and nine months ended September 30, 2012 include the operations of Liberty, EAV, our European Operations, our acute infusion therapies line of business, and UBC subsequent to the date of the Merger, April 2, 2012 (revised to reflect the operations as discontinued operations as applicable). The following presentation reflects the structure that exists as of the most recent balance sheet date and also includes certain retrospective revisions to conform prior periods to current period presentation (discussed and presented in further detail below). The condensed consolidating financial information is presented separately for:

(i) Express Scripts (the Parent Company), the issuer of certain guaranteed obligations;

(ii) ESI, guarantor, the issuer of additional guaranteed obligations;

(iii) Medco, guarantor, the issuer of additional guaranteed obligations;

(iv) Guarantor subsidiaries, on a combined basis (but excluding ESI and Medco), as specified in the indentures related to Express Scripts’, ESI’s and Medco’s obligations under the notes;

(v) Non-guarantor subsidiaries, on a combined basis;

(vi) Consolidating entries and eliminations representing adjustments to (a) eliminate intercompany transactions between or among Express Scripts, ESI, Medco, the guarantor subsidiaries and the non-guarantor subsidiaries, (b) eliminate the investments in our subsidiaries and (c) record consolidating entries; and

(vii) Express Scripts and its subsidiaries on a consolidated basis.

Certain amounts from prior periods have been reclassified to conform to current period presentation:

(i) With respect to the condensed consolidating statement of operations for the three and nine months ended September 30, 2012, amounts related to net income attributable to non-controlling interest have been reclassified from the “Operating expenses” line item to the “Net income attributable to non-controlling interest” line item as follows:

	Three months ended						Nine months ended
	September 30, 2012						September 30, 2012
(in millions)	Non-Guarantors			Consolidated			Non-Guarantors			Consolidated
Operating Expenses	$	(4.5	)	$	(4.5	)	$	(10.3	)	$	(10.3	)
Net income attributable to non-controlling interest	$	4.5		$	4.5		$	10.3		$	10.3

23

(ii) With respect to the condensed consolidating statement of cash flows for the nine months ended September 30, 2012, amounts related to distributions paid to non-controlling interest have been reclassified from the “Net cash flows provided by (used in) operating activities” line item to the “Distributions paid to non-controlling interest” line item within the cash flows from financing activities section, as follows:

(in millions)	Non-Guarantors			Consolidated
Net cash flows provided by (used in) operating activities	$	5.3		$	5.3
Distributions paid to non-controlling interest	$	(5.3	)	$	(5.3	)

(iii) As noted in Exhibit 99.6 to the S-4 filed November 19, 2012, with respect to the condensed consolidating statement of operations for the three and nine months ended September 30, 2012, amounts related to certain intercompany revenues and operating expenses were not recorded on a gross basis within the respective columns and certain operating expenses were not appropriately allocated to the respective column. The impact of the revision is to increase revenue and operating expenses in the Non-Guarantors column by $290.1 million and $558.6 million for the three and nine months ended September 30, 2012, respectively, offset by corresponding decreases of $290.1 million and $558.6 million in the Eliminations column.

(iv) With respect to the condensed consolidating balance sheet as of December 31, 2012, amounts related to the goodwill allocated to Medco Health Solutions, Inc. and certain of its guarantor and non-guarantor subsidiaries have changed as we finalized the purchase price allocation in the first quarter of 2013. The impact of the measurement period adjustment is to reallocate goodwill and intercompany amounts as follows:

(in millions)	Medco Health Solutions, Inc.			Guarantors			Non-guarantors			Eliminations
Intercompany assets	$	(2,040.0	)	$	2,000.5		$	—		$	39.5
Goodwill	$	2,040.0		$	(2,000.5	)	$	39.5		$	—
Intercompany liabilities	$	—		$	—		$	(39.5	)	$	39.5

24

Condensed Consolidating Balance Sheet
(in millions)	Express Scripts Holding Company		Express Scripts, Inc.		Medco Health Solutions, Inc.		Guarantors		Non-Guarantors		Eliminations			Consolidated
As of September 30, 2013
Cash and cash equivalents	$	—	$	1,140.7	$	3.4	$	143.4	$	434.8	$	—		$	1,722.3
Restricted cash and investments	—		—		1.0		—		18.2		—			19.2
Receivables, net	—		1,230.6		1,882.8		1,533.8		465.2		—			5,112.4
Other current assets	—		126.2		294.2		1,794.9		30.0		—			2,245.3
Current assets of discontinued operations	—		—		—		56.0		69.0		—			125.0
Total current assets	—		2,497.5		2,181.4		3,528.1		1,017.2		—			9,224.2
Property and equipment, net	—		478.6		—		1,129.4		21.2		—			1,629.2
Investments in subsidiaries	32,883.2		8,844.0		5,343.3		—		—		(47,070.5		)	—
Intercompany	560.1		—		161.6		7,592.0		—		(8,313.7		)	—
Goodwill	—		2,921.4		22,608.2		3,750.2		26.5		—			29,306.3
Other intangible assets, net	55.5		1,101.4		11,363.4		1,985.4		20.2		—			14,525.9
Other assets	—		77.9		12.5		0.3		2.4		(36.5		)	56.6
Noncurrent assets of discontinued operations	—		—		—		11.8		9.0		—			20.8
Total assets	$	33,498.8	$	15,920.8	$	41,670.4	$	17,997.2	$	1,096.5	$	(55,420.7	)	$	54,763.0
Claims and rebates payable	$	—	$	2,751.4	$	3,706.1	$	—	$	2.2	$	—		$	6,459.7
Accounts payable	—		631.9		65.1		1,795.6		80.8		—			2,573.4
Accrued expenses	80.7		109.0		125.5		951.2		230.3		—			1,496.7
Current maturities of long-term debt	631.6		—		—		—		—		—			631.6
Current liabilities of discontinued operations	—		—		—		20.0		44.8		—			64.8
Total current liabilities	712.3		3,492.3		3,896.7		2,766.8		358.1		—			11,226.2
Long-term debt	9,084.2		1,994.5		2,403.3		—		—		—			13,482.0
Intercompany	—		8,138.6		—		—		175.1		(8,313.7		)	—
Deferred taxes	—		—		4,123.0		1,455.7		10.3		—			5,589.0
Other liabilities	—		184.1		475.5		101.2		22.0		(36.5		)	746.3
Noncurrent liabilities of discontinued operations	—		—		—		—		0.4		—			0.4
Non-controlling interest	—		—		—		—		16.8		—			16.8
Express Scripts stockholders’ equity	23,702.3		2,111.3		30,771.9		13,673.5		513.8		(47,070.5		)	23,702.3
Total liabilities and stockholders’ equity	$	33,498.8	$	15,920.8	$	41,670.4	$	17,997.2	$	1,096.5	$	(55,420.7	)	$	54,763.0

25

Condensed Consolidating Balance Sheet
(in millions)	Express Scripts Holding Company		Express Scripts, Inc.		Medco Health Solutions, Inc.		Guarantors		Non-Guarantors		Eliminations			Consolidated
As of December 31, 2012
Cash and cash equivalents	$	—	$	2,346.6	$	—	$	126.9	$	319.6	$	—		$	2,793.1
Restricted cash and investments	—		—		—		1.0		18.6		—			19.6
Receivables, net	—		1,097.8		2,330.0		1,493.0		505.0		—			5,425.8
Other current assets	—		119.2		306.6		1,800.4		20.8		—			2,247.0
Current assets of discontinued operations	—		—		—		73.4		198.0		—			271.4
Total current assets	—		3,563.6		2,636.6		3,494.7		1,062.0		—			10,756.9
Property and equipment, net	—		305.7		—		1,307.2		19.2		—			1,632.1
Investments in subsidiaries	31,375.6		8,292.7		5,121.0		—		—		(44,789.3		)	—
Intercompany	2,189.0		—		926.8		6,127.2		—		(9,243.0		)	—
Goodwill	—		2,921.4		22,621.5		3,750.3		27.2		—			29,320.4
Other intangible assets, net	67.1		1,192.4		12,609.4		2,153.6		15.4		—			16,037.9
Other assets	—		57.4		14.4		5.9		4.7		(26.3		)	56.1
Noncurrent assets of discontinued operations	—		—		—		42.1		265.7		—			307.8
Total assets	$	33,631.7	$	16,333.2	$	43,929.7	$	16,881.0	$	1,394.2	$	(54,058.6	)	$	58,111.2
Claims and rebates payable	$	—	$	2,554.1	$	4,885.9	$	—	$	—	$	—		$	7,440.0
Accounts payable	—		477.5		—		2,284.5		136.9		—			2,898.9
Accrued expenses	62.9		428.3		327.8		612.0		201.9		—			1,632.9
Current maturities of long-term debt	631.6		0.1		303.2		—		—		—			934.9
Current liabilities of discontinued operations	—		—		—		7.3		143.4		—			150.7
Total current liabilities	694.5		3,460.0		5,516.9		2,903.8		482.2		—			13,057.4
Long-term debt	9,552.2		2,992.1		2,435.8		—		—		—			14,980.1
Intercompany	—		8,764.5		—		—		478.5		(9,243.0		)	—
Deferred taxes	—		—		5,074.7		861.8		—		—			5,936.5
Other liabilities	—		158.7		484.6		73.1		2.8		(26.3		)	692.9
Noncurrent liabilities of discontinued operations	—		—		—		12.3		36.3		—			48.6
Non-controlling interest	—		—		—		—		10.7		—			10.7
Express Scripts stockholders’ equity	23,385.0		957.9		30,417.7		13,030.0		383.7		(44,789.3		)	23,385.0
Total liabilities and stockholders’ equity	$	33,631.7	$	16,333.2	$	43,929.7	$	16,881.0	$	1,394.2	$	(54,058.6	)	$	58,111.2

26

Condensed Consolidating Statement of Operations
(in millions)	Express Scripts Holding Company			Express Scripts, Inc.			Medco Health Solutions, Inc.			Guarantors			Non-Guarantors			Eliminations			Consolidated
For the three months ended September 30, 2013
Revenues	$	—		$	7,633.8		$	13,040.7		$	5,792.2		$	528.0		$	(1,079.1	)	$	25,915.6
Operating expenses	—			7,224.7			13,118.9			5,472.9			302.7			(1,079.1		)	25,040.1
Operating income (expense)	—			409.1			(78.2		)	319.3			225.3			—			875.5
Other (expense) income, net	(85.6		)	(16.8		)	9.2			0.5			(2.7		)	—			(95.4		)
Income (loss) before income taxes	(85.6		)	392.3			(69.0		)	319.8			222.6			—			780.1
Provision (benefit) for income taxes	(31.0		)	152.9			5.2			166.2			33.2			—			326.5
Net (loss) income from continuing operations	(54.6		)	239.4			(74.2		)	153.6			189.4			—			453.6
Net (loss) income from discontinued operations, net of tax	—			—			—			(36.0		)	20.5			—			(15.5		)
Equity in earnings of subsidiaries	481.3			180.9			135.2			—			—			(797.4		)	—
Net income	$	426.7		$	420.3		$	61.0		$	117.6		$	209.9		$	(797.4	)	$	438.1
Less: Net income attributable to non-controlling interest	—			—			—			—			11.4			—			11.4
Net income attributable to Express Scripts	426.7			420.3			61.0			117.6			198.5			(797.4		)	426.7
Other comprehensive income	2.5			2.5			—			—			2.5			(5.0		)	2.5
Comprehensive income attributable to Express Scripts	$	429.2		$	422.8		$	61.0		$	117.6		$	201.0		$	(802.4	)	$	429.2

27

Condensed Consolidating Statement of Operations
(in millions)	Express Scripts Holding Company			Express Scripts, Inc.			Medco Health Solutions, Inc.			Guarantors			Non-Guarantors			Eliminations			Consolidated
For the three months ended September 30, 2012
Revenues	$	—		$	7,282.3		$	14,137.2		$	5,771.0		$	275.2		$	(704.1	)	$	26,761.6
Operating expenses	—			6,957.5			13,951.0			5,509.9			226.6			(704.1		)	25,940.9
Operating income	—			324.8			186.2			261.1			48.6			—			820.7
Other expense, net	(95.5		)	(30.8		)	(15.4		)	(3.3		)	(3.7		)	—			(148.7		)
Income (loss) before income taxes	(95.5		)	294.0			170.8			257.8			44.9			—			672.0
Provision (benefit) for income taxes	(41.4		)	114.1			65.4			105.7			12.3			—			256.1
Net (loss) income from continuing operations	(54.1		)	179.9			105.4			152.1			32.6			—			415.9
Net loss from discontinued operations, net of tax	—			—			—			(4.7		)	(15.3		)	—			(20.0		)
Equity in earnings of subsidiaries	445.5			183.3			(23.1		)	—			—			(605.7		)	—
Net income	391.4			363.2			82.3			147.4			17.3			(605.7		)	395.9
Less: Net income attributable to non-controlling interest	—			—			—			—			4.5			—			4.5
Net income attributable to Express Scripts	391.4			363.2			82.3			147.4			12.8			(605.7		)	391.4
Other comprehensive income	8.5			3.8			4.7			—			8.5			(17.0		)	8.5
Comprehensive income attributable to Express Scripts	$	399.9		$	367.0		$	87.0		$	147.4		$	21.3		$	(622.7	)	$	399.9

28

Condensed Consolidating Statement of Operations
(in millions)	Express Scripts Holding Company			Express Scripts, Inc.			Medco Health Solutions, Inc.			Guarantors			Non-Guarantors			Eliminations			Consolidated
For the nine months ended September 30, 2013
Revenues	$	—		$	21,887.4		$	40,826.2		$	17,128.6		$	1,114.1		$	(2,638.9	)	$	78,317.4
Operating expenses	—			20,725.0			40,541.5			16,227.0			739.9			(2,638.9		)	75,594.5
Operating income	—			1,162.4			284.7			901.6			374.2			—			2,722.9
Other (expense) income, net	(259.1		)	(133.8		)	(20.6		)	2.6			(8.0		)	—			(418.9		)
Income (loss) before income taxes	(259.1		)	1,028.6			264.1			904.2			366.2			—			2,304.0
Provision (benefit) for income taxes	(94.2		)	426.4			132.3			391.9			39.6			—			896.0
Net (loss) income from continuing operations	(164.9		)	602.2			131.8			512.3			326.6			—			1,408.0
Net (loss) income from discontinued operations, net of tax	—			—			—			(42.3		)	1.0			—			(41.3		)
Equity in earnings of subsidiaries	1,507.6			551.3			222.3			—			—			(2,281.2		)	—
Net income	1,342.7			1,153.5			354.1			470.0			327.6			(2,281.2		)	1,366.7
Less: Net income attributable to non-controlling interest	—			—			—			—			24.0			—			24.0
Net income attributable to Express Scripts	1,342.7			1,153.5			354.1			470.0			303.6			(2,281.2		)	1,342.7
Other comprehensive loss	(3.5		)	(3.5		)	—			—			(3.5		)	7.0			(3.5		)
Comprehensive income attributable to Express Scripts	$	1,339.2		$	1,150.0		$	354.1		$	470.0		$	300.1		$	(2,274.2	)	$	1,339.2

29

Condensed Consolidating Statement of Operations
(in millions)	Express Scripts Holding Company			Express Scripts, Inc.			Medco Health Solutions, Inc.			Guarantors			Non-Guarantors			Eliminations			Consolidated
For the nine months ended September 30, 2012
Revenues	$	—		$	22,360.3		$	28,642.1		$	16,180.2		$	690.5		$	(1,523.9	)	$	66,349.2
Operating expenses	—			21,395.6			28,582.8			15,458.4			549.3			(1,523.9		)	64,462.2
Operating income	—			964.7			59.3			721.8			141.2			—			1,887.0
Other expense, net	(251.4		)	(148.3		)	(35.5		)	(3.3		)	(7.7		)	—			(446.2		)
Income (loss) before income taxes	(251.4		)	816.4			23.8			718.5			133.5			—			1,440.8
Provision (benefit) for income taxes	(97.6		)	364.2			9.1			304.8			22.0			—			602.5
Net income (loss) from continuing operations	(153.8		)	452.2			14.7			413.7			111.5			—			838.3
Net loss from discontinued operations, net of tax	—			—			—			(3.5		)	(15.7		)	—			(19.2		)
Equity in earnings of subsidiaries	962.6			463.4			32.3			—			—			(1,458.3		)	—
Net income	808.8			915.6			47.0			410.2			95.8			(1,458.3		)	819.1
Less: Net income attributable to non-controlling interest	—			—			—			—			10.3			—			10.3
Net income attributable to Express Scripts	808.8			915.6			47.0			410.2			85.5			(1,458.3		)	808.8
Other comprehensive (loss) income	(0.4		)	3.1			(3.5		)	—			(0.4		)	0.8			(0.4		)
Comprehensive income attributable to Express Scripts	$	808.4		$	918.7		$	43.5		$	410.2		$	85.1		$	(1,457.5	)	$	808.4

30

Condensed Consolidating Statements of Cash Flows
(in millions)	Express Scripts Holding Company			Express Scripts, Inc.			Medco Health Solutions, Inc.			Guarantors			Non- Guarantors			Eliminations			Consolidated
For the nine months ended September 30, 2013
Net cash flows provided by (used in) operating activities	$	(129.8	)	$	759.4		$	70.6		$	721.6		$	411.3		$	(10.7	)	$	1,822.4
Cash flows from investing activities:
Proceeds from sale of business	—			1.6			—			311.4			—			—			313.0
Purchases of property and equipment	—			(261.4		)	—			(8.0		)	(5.2		)	—			(274.6		)
Acquisitions	—			—			—			—			(14.5		)	—			(14.5		)
Other	—			(17.8		)	—			—			6.0			—			(11.8		)
Net cash provided by (used in) investing activities - continuing operations	—			(277.6		)	—			303.4			(13.7		)	—			12.1
Net cash used in investing activities - discontinued operations	—			—			—			(0.1		)	(2.0		)	—			(2.1		)
Net cash provided by (used in) investing activities	—			(277.6		)	—			303.3			(15.7		)	—			10.0
Cash flows from financing activities:
Repayment of long term debt	(473.7		)	(1,000.0		)	(300.0		)	—			—			—			(1,773.7		)
Treasury stock acquired	(1,552.5		)	—			—			—			—			—			(1,552.5		)
Net proceeds from employee stock plans	383.6			—			—			—			—			—			383.6
Excess tax benefit relating to employee stock compensation	—			11.8			11.4			—			—			—			23.2
Distributions paid to non-controlling interest	—			—			—			—			(18.0		)	—			(18.0		)
Other	—			—			—			(8.5		)	23.9			—			15.4
Net intercompany transactions	1,772.4			(699.5		)	221.4			(999.9		)	(294.4		)	—			—
Net cash (used in) provided by financing activities - continuing operations	129.8			(1,687.7		)	(67.2		)	(1,008.4		)	(288.5		)	—			(2,922.0		)
Net cash used in financing activities - discontinued operations	—			—			—			—			(10.7		)	10.7			—
Net cash (used in) provided by financing activities	129.8			(1,687.7		)	(67.2		)	(1,008.4		)	(299.2		)	10.7			(2,922.0		)
Effect of foreign currency translation adjustment	—			—			—			—			(4.5		)	—			(4.5		)
Less: cash decrease attributable to discontinued operations	—			—			—			—			23.3			—			23.3
Net (decrease) increase in cash and cash equivalents	—			(1,205.9		)	3.4			16.5			115.2			—			(1,070.8		)
Cash and cash equivalents at beginning of period	—			2,346.6			—			126.9			319.6			—			2,793.1
Cash and cash equivalents at end of period	$	—		$	1,140.7		$	3.4		$	143.4		$	434.8		$	—		$	1,722.3

31

Condensed Consolidating Statements of Cash Flows
(in millions)	Express Scripts Holding Company			Express Scripts, Inc.			Medco Health Solutions, Inc.			Guarantors			Non- Guarantors			Eliminations		Consolidated
For the nine months ended September 30, 2012
Net cash flows provided by (used in) operating activities	$	(63.3	)	$	549.4		$	1,535.0		$	202.7		$	(169.1	)	$	—	$	2,054.7
Cash flows from investing activities:
Proceeds from the sale of business	—			31.5			—			—			—			—		31.5
Purchases of property and equipment	—			(50.4		)	—			(50.9		)	(0.6		)	—		(101.9		)
Acquisitions, net of cash acquired	(10,283.6		)	—			—			0.4			(42.8		)	—		(10,326.0		)
Other	—			(3.9		)	—			—			(12.3		)	—		(16.2		)
Net cash used in investing activities - continuing operations	(10,283.6		)	(22.8		)	—			(50.5		)	(55.7		)	—		(10,412.6		)
Acquisitions, cash acquired - discontinued operations	—			—			—			—			42.4			—		42.4
Net cash used in investing activities - discontinued operations	—			—			—			—			(4.1		)	—		(4.1		)
Net cash used in investing activities	(10,283.6		)	(22.8		)	—			(50.5		)	(17.4		)	—		(10,374.3		)
Cash flows from financing activities:
Repayment of long term debt	(210.5		)	(1,000.1		)	(1,500.0		)	—			—			—		(2,710.6		)
Net proceeds from employee stock plans	245.7			—			30.8			—			—			—		276.5
Excess tax benefit (expense) relating to employee stock compensation	—			29.0			1.4			—			—			—		30.4
Distributions paid to non-controlling interest	—			—			—			—			(5.3		)	—		(5.3		)
Proceeds from long-term debt, net of discounts	7,458.9			—			—			—			—			—		7,458.9
Repayment of revolving credit line, net	—			—			(1,000.0		)	—			—			—		(1,000.0		)
Proceeds from accounts receivable financing facility	—			—			—			—			600.0			—		600.0
Repayment of accounts receivable financing facility	—			—			—			—			(600.0		)	—		(600.0		)
Other	(52.4		)	(50.8		)	—			—			—			—		(103.2		)
Net intercompany transactions	2,905.2			(4,052.0		)	934.6			(115.5		)	327.7			—		—
Net cash provided by (used in) financing activities - continuing operations	10,346.9			(5,073.9		)	(1,533.2		)	(115.5		)	322.4			—		3,946.7
Net cash used in financing activities - discontinued operations	—			—			—			—			(1.3		)	—		(1.3		)
Net cash provided by (used in) financing activities	10,346.9			(5,073.9		)	(1,533.2		)	(115.5		)	321.1			—		3,945.4
Effect of foreign currency translation adjustment	—			—			—			—			2.6			—		2.6
Less: cash increase attributable to discontinued operations	—			—			—			0.4			(47.7		)	—		(47.3		)
Net (decrease) increase in cash and cash equivalents	—			(4,547.3		)	1.8			37.1			89.5			—		(4,418.9		)
Cash and cash equivalents at beginning of period	—			5,522.2			—			5.4			92.5			—		5,620.1
Cash and cash equivalents at end of period	$	—		$	974.9		$	1.8		$	42.5		$	182.0		$	—	$	1,201.2

32

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Forward Looking Statements and Associated Risks

Information we have included in this Quarterly Report on Form 10-Q, and information which may be contained in our other filings with the Securities and Exchange Commission (the “SEC”) and our press releases or other public statements, contain or may contain forward-looking statements. These forward-looking statements include, among others, statements of our plans, objectives, expectations (financial or otherwise) or intentions.

Our forward-looking statements involve risks and uncertainties. Our actual results may differ significantly from those projected or suggested in any forward-looking statements. We do not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances occurring after the date hereof or to reflect the occurrence of unanticipated events. Any number of factors could cause our actual results to differ materially from those contemplated by any forward-looking statements, including, but not limited to the factors listed below:

• our ability to remain profitable in a very competitive marketplace depends upon our continued ability to attract and retain clients while maintaining our margins, to differentiate our products and services from those of our competitors in the marketplace, and to develop and cross-sell new products and services to our existing clients

• our failure to anticipate and appropriately adapt to changes or trends within the rapidly changing healthcare industry

• changes in applicable laws, rules or regulations, or their interpretation or enforcement, or the enactment of new laws, rules or regulations, which apply to our business practices (past, present or future) or require us to spend significant resources in order to comply or to make significant changes to our business operations

• unfavorable or uncertain economic conditions, including high rates of unemployment, diminished health care benefits, lower levels of consumer expenditures on health care related expenses, increased client demands with respect to pricing or service levels, or disruptions in the credit markets

• changes to the healthcare industry designed to manage healthcare costs or alter healthcare financing practices

• uncertainties regarding the implementation of Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (“Health Reform Laws”)

• significant changes within the pharmacy provider marketplace, including the loss of or adverse change in our relationship with one or more key pharmacy providers

• our failure to execute on, or other issues arising under, certain key client contracts

• changes relating to our participation in Medicare Part D, the loss of Medicare Part D eligible members, or our failure to otherwise execute on our strategies related to Medicare Part D

• our failure to effectively execute on strategic transactions or successfully integrate the business operations or achieve the anticipated benefits from any acquired businesses

• uncertainty around realization of the anticipated benefits of the transaction with Medco, including the expected amount and timing of cost savings and operating synergies and a delay or difficulty in integrating the businesses of Express Scripts, Inc. and Medco or in retaining clients of the respective companies

• the impact of our debt service obligations on the availability of funds for other business purposes, and the terms of and our required compliance with covenants relating to our indebtedness

• a failure in the security or stability of our technology infrastructure, or the infrastructure of one or more of our key vendors, or a significant failure or disruption in service within our operations or the operations of such vendors

• a failure to adequately protect confidential health information received and used in our business operations

• the termination, or an unfavorable modification, of our relationship with one or more key pharmaceutical manufacturers, or the significant reduction in payments made or discounts provided by pharmaceutical manufacturers

• changes in industry pricing benchmarks

• results in pending and future litigation or other proceedings which could subject us to significant monetary damages or penalties and/or require us to change our business practices, or the costs incurred in connection with such proceedings

• our failure to attract and retain talented employees, or to manage succession and retention for our Chief Executive Officer or other key executives

• regulatory, compliance, competition and tax risks inherent in our international operations

• other risks described from time to time in our filings with the SEC

See the more comprehensive description of risk factors under the captions “Forward Looking Statements and Associated Risks” contained in Item 1 - “Business” and Item 1A - “Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2012, filed with the SEC on February 19, 2013.

33

These and other relevant factors and any other information included in this Report, and information which may be contained in our other filings with the SEC, should be carefully considered when reviewing any forward-looking statement. We note these factors for investors as permitted under the Private Securities Litigation Reform Act of 1995. Investors should understand that it is impossible to predict or identify all such factors or risks. As such, you should not consider either foregoing lists, or the risks identified in our SEC filings, to be a complete discussion of all potential risks or uncertainties.

34

OVERVIEW

On July 20, 2011, Express Scripts, Inc. (“ESI”) entered into a definitive merger agreement (the “Merger Agreement”) with Medco Health Solutions, Inc. (“Medco”), which was amended by Amendment No. 1 thereto on November 7, 2011, providing for the combination of ESI and Medco under a new holding company named Aristotle Holding, Inc. The transactions contemplated by the Merger Agreement (the “Merger”) were consummated on April 2, 2012. Aristotle Holding, Inc. was renamed Express Scripts Holding Company (the “Company” or “Express Scripts”) concurrently with the consummation of the Merger. “We,” “our” or “us” refers to Express Scripts Holding Company and its subsidiaries. For financial reporting and accounting purposes, ESI was the acquirer of Medco. The consolidated financial statements (and other data, such as claims volume) reflect the results of operations and financial position of ESI for the period beginning January 1, 2012 through April 1, 2012. However, references to amounts for periods after the closing of the Merger on April 2, 2012 relate to Express Scripts.

As the largest full-service pharmacy benefit management (“PBM”) company in the United States, we provide healthcare management and administration services on behalf of our clients, which include managed care organizations, health insurers, third-party administrators, employers, union-sponsored benefit plans, workers’ compensation plans and government health programs. Our integrated PBM services include network claims processing, home delivery services, patient care and direct specialty and fertility home delivery to patients, benefit plan design consultation, drug utilization review, formulary management, drug data analysis services, distribution of injectable drugs to patients’ homes and physicians’ offices, bio-pharma services and fulfillment of prescriptions to low-income patients through manufacturer-sponsored patient assistance programs.

Through our Other Business Operations segment, we distribute pharmaceuticals and medical supplies to providers and clinics, as well as provide scientific evidence to guide the safe, effective and affordable use of medicines.

Revenue generated by our segments can be classified as either tangible product revenue or service revenue. We earn tangible product revenue from the sale of prescription drugs by retail pharmacies in our retail pharmacy networks and from dispensing prescription drugs from our home delivery and specialty pharmacies. Service revenue includes administrative fees associated with the administration of retail pharmacy networks contracted by certain clients, medication counseling services and certain specialty distribution services. Tangible product revenue generated by our PBM and Other Business Operations segments represented 98.9% of revenues for the three months ended September 30, 2013 and 2012, and 98.8% and 99.0% of revenues for the nine months ended September 30, 2013 and 2012, respectively.

MERGER TRANSACTION

As a result of the Merger on April 2, 2012, Medco and ESI each became wholly owned subsidiaries of Express Scripts and former Medco and ESI stockholders became owners of Express Scripts stock, which is listed for trading on the Nasdaq. Upon closing of the Merger, former ESI stockholders owned approximately 59% of Express Scripts and former Medco stockholders owned approximately 41% of Express Scripts.

EXECUTIVE SUMMARY AND TREND FACTORS AFFECTING THE BUSINESS

Our results in 2013 compared to prior periods continue to be driven by the addition of Medco to our book of business on April 2, 2012. The Merger impacted all components of our financial statements, including our revenues, expenses and profits, the consolidated balance sheet, as well as claims volumes. Our results reflect the ability to successfully achieve synergies following the Merger. Our results also reflect the successful execution of our business model, which emphasizes the alignment of our financial interests with those of our clients through greater use of generics and low-cost brands, home delivery and specialty pharmacy. We also benefited from better management of ingredient costs through renegotiation of supplier contracts, increased competition among generic manufacturers and a higher generic fill rate (80.7% for the nine months ended September 30, 2013 compared to 78.0% in the same period of 2012). In addition, we are providing our clients with additional tools designed to generate higher generic fill rates, further increase the use of our home delivery and specialty pharmacy services and drive greater adherence.

We anticipate that the current business climate may continue to adversely affect our near-term results, including through such factors as lower membership and utilization resulting from in-group attrition at the client level and continued low utilization rates generally. We will also face challenges due to various marketplace forces which affect pricing and plan structures, as well as increasing client demands and expectations. However, we expect that ongoing positive trends in our business will continue to offset these negative factors, allowing us to continue to generate growth and improvements in our results of operations in the future, although these negative factors will temper our growth rate over the near term. As a result of the transition of UnitedHealth Group Incorporated claims and variability of other contractual revenue streams, quarterly performance trends may vary from historical periods. As expected, revenue related to a large client was realized in the second quarter of 2013 due to the structure of the contract. The Company anticipates this pattern of earnings to continue for the foreseeable future.

35

As the regulatory environment evolves, we plan to continue to make investments designed to keep us ahead of the competition. These projects include preparation for changes to the Medicare regulations and the implementation of the Health Reform Laws.

CRITICAL ACCOUNTING POLICIES

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Our estimates and assumptions are based upon a combination of historical information and various other assumptions believed to be reasonable under the particular circumstances. Actual results may differ from our estimates. For a full description of our critical accounting policies, please refer to “Management’s Discussion and Analysis of Financial Condition and Results of Operations – Critical Accounting Policies” included in Express Scripts’ Annual Report on Form 10-K for the year ended December 31, 2012, filed with the SEC on February 19, 2013.

CLIENTS

We are a provider of PBM services to several market segments. Our clients include managed care organizations, health insurers, third-party administrators, employers, union-sponsored benefit plans, workers’ compensation plans and government health programs. We provide specialty services to customers who also include managed care organizations, health insurers, third-party administrators, employers, union-sponsored benefit plans, government health programs, office-based oncologists, renal dialysis clinics, ambulatory surgery centers, primary care physicians, retina specialists and others. Refer to Note 11 - Segment information for a discussion of client concentration.

RESULTS OF OPERATIONS

PBM OPERATING INCOME

We report segments on the basis of services offered and have determined we have two reportable segments: PBM and Other Business Operations. Our PBM segment includes our integrated PBM operations and specialty pharmacy operations. Our Other Business Operations segment includes the continuing operations portion of United BioSource LLC (“UBC”) and our Specialty Distribution operations.

Prior to the Merger, ESI and Medco historically used slightly different methodologies to report claims; however, we believe the differences between the claims reported by ESI and Medco would not be material had the same methodology applied. We have since combined these two approaches into one methodology to be used by the Company. This change was made prospectively beginning April 2, 2012. We have not restated the number of claims in prior periods, because the differences are not material.

36

During the three months ended September 30, 2013, we determined that a business acquired in the Merger that was previously included within our PBM segment was no longer core to our future operations and committed to a plan to dispose of this business. In accordance with applicable accounting guidance, the results of operations for this business is reported as discontinued operations for all periods presented in the accompanying information provided below.

	Three Months Ended September 30,				Nine Months Ended September 30,
(in millions)	2013		2012		2013		2012
Product revenues
Network revenues(1)	$	15,387.3	$	16,341.9	$	47,758.8	$	40,860.5
Home delivery and specialty revenues(2)	9,705.7		9,531.8		28,164.1		23,254.5
Service revenues	237.7		233.7		750.5		563.6
Total PBM revenues	25,330.7		26,107.4		76,673.4		64,678.6
Cost of PBM revenues(1)	23,370.8		24,080.7		70,702.0		59,831.3
PBM gross profit	1,959.9		2,026.7		5,971.4		4,847.3
PBM SG&A expenses	1,096.6		1,185.1		3,285.1		2,936.9
PBM operating income	$	863.3	$	841.6	$	2,686.3	$	1,910.4
Claims(3)
Network	256.9		282.9		805.9		721.5
Home delivery and specialty(2)	34.6		37.7		106.6		89.9
Total PBM claims	291.5		320.6		912.5		811.4
Total adjusted PBM claims(4)	358.1		392.8		1,117.3		982.8

(1) Includes retail pharmacy co-payments of $2,966.5 million and $3,348.9 million for the three months ended September 30, 2013 and 2012, respectively, and $9,845.2 million and $8,364.6 million for the nine months ended September 30, 2013 and 2012, respectively.

(2) Includes home delivery, specialty and other including: (a) drugs distributed through patient assistance programs, (b) drugs we distribute to other PBMs’ clients under limited distribution contracts with pharmaceutical manufacturers, and (c) FreedomFP claims.

(3) Claims are calculated based on an updated methodology starting April 2, 2012. The prior periods have not been recalculated using the new methodology because we believe the differences would not be material, as discussed above.

(4) Total adjusted claims reflect home delivery claims multiplied by 3, as home delivery claims typically cover a time period 3 times longer than retail claims.

Product Revenues for the three months ended September 30, 2013: Network pharmacy revenues decreased by $954.6 million, or 5.8%, in the three months ended September 30, 2013 over the same period of 2012. The decrease relates primarily to lower claims volume including the transition of UnitedHealth Group Incorporated claims and an increase in the network generic fill rate. Our consolidated network generic fill rate increased to 81.6% of network claims in the three months ended September 30, 2013 as compared to 79.7% in the same period of 2012.

Home delivery and specialty revenues increased$173.9 million, or 1.8%, in the three months ended September 30, 2013 from the same period in 2012. The increase is primarily due to inflation on branded drugs offset by lower claims volume including the transition of UnitedHealth Group Incorporated claims and an increase in the home delivery generic fill rate. Our consolidated home delivery generic fill rate increased to 74.8% of home delivery claims in the three months ended September 30, 2013 as compared to 72.2% in the same period of 2012.

Product Revenues for the nine months ended September 30, 2013: Network pharmacy revenues increased by $6,898.3 million, or 16.9%, in the nine months ended September 30, 2013. Approximately $9,131.7 million of this increase relates to the acquisition of Medco and inclusion of its revenues and associated claims for the three months ended March 31, 2013. This increase is offset by lower claims volume including the transition of UnitedHealth Group Incorporated claims and an increase in the network generic fill rate. Our consolidated network generic fill rate increased to 81.6% of network claims in the nine months ended September 30, 2013 as compared to 78.9% in the same period of 2012.

Home delivery and specialty revenues increased by $4,909.6 million, or 21.1%, in the nine months ended September 30, 2013 from the same period in 2012. Approximately $5,216.8 million of this increase relates to the acquisition of Medco and inclusion of its revenues and associated claims for the three months ended March 31, 2013. This increase is also due to inflation on branded drugs, offset by lower claims volume including the transition of UnitedHealth Group Incorporated claims and by an

37

increase in the home delivery generic fill rate. Our consolidated home delivery generic fill rate increased to 74.5% of home delivery claims in the nine months ended September 30, 2013 as compared to 70.6% in the same period of 2012.

Cost of PBM revenues decreased by $709.9 million, or 2.9%, in the three months ended September 30, 2013 from the same period of 2012. The decrease is primarily due to lower claims volume including the transition of UnitedHealth Group Incorporated claims and an increase in the generic fill rate partially offset by inflation on branded drugs as well as $56.8 million of transaction and integration costs for the three months ended September 30, 2013 compared to $21.8 million for the three months ended September 30, 2012.

Cost of PBM revenues increased by $10,870.7 million, or 18.2%, in the nine months ended September 30, 2013 from the same period of 2012. Approximately $13,416.8 million of this increase relates to the acquisition of Medco and inclusion of its costs of revenues for the three months ended March 31, 2013. In addition, this increase is due to inflation on branded drugs as well as $137.9 million of transaction and integration costs for the nine months ended September 30, 2013 compared to $33.7 million for the nine months ended September 30, 2012. These increases are partially offset by lower claims volume including the transition of UnitedHealth Group Incorporated claims and an increase in the generic fill rate.

PBM gross profit decreased by $66.8 million, or 3.3% in the three months ended September 30, 2013 from the same period of 2012. The decrease is primarily due to lower claims volume including the transition of UnitedHealth Group Incorporated claims. This decrease is partially offset by an increase in the generic fill rate.

PBM gross profit increased by $1,124.1 million, or 23.2%, in the nine months ended September 30, 2013 from the same period of 2012. This increase relates to the acquisition of Medco and inclusion of its gross profit for the three months ended March 31, 2013, as discussed above. In addition, this increase is a result of better management of ingredient costs and cost savings from the increase in the generic fill rate partially offset by lower claims volume including the transition of UnitedHealth Group Incorporated claims.

SG&A for our PBM segment for the three months ended September 30, 2013decreased by $88.5 million, or 7.5%, as compared to the same period of 2012. The decrease primarily relates to synergies realized as a result of the Merger and $130.8 million of transaction and integration costs for the combined Company, compared to $158.9 million for the three months ended September 30, 2012.

SG&A for our PBM segment for the nine months ended September 30, 2013increased by $348.2 million, or 11.9%, as compared to the same period of 2012. Approximately $832.9 million of this increase related to the acquisition of Medco, due primarily to the inclusion of its SG&A and the amortization of intangible assets acquired. This increase is partially offset by synergies realized as a result of the Merger, $349.7 million of transaction and integration costs for the combined Company, compared to $565.9 million for the nine months ended September 30, 2012, and decreased management incentive compensation.

PBM operating income increased by $21.7 million, or 2.6%, and $775.9 million, or 40.6%, for the three and ninemonths ended September 30, 2013, respectively, as compared to the same periods of 2012, based on the various factors described above.

OTHER BUSINESS OPERATIONS OPERATING INCOME

During 2012, we determined that various businesses acquired in the Merger that were previously included within our Other Business Operations segment were no longer core to our future operations and committed to a plan to dispose of these businesses. In accordance with applicable accounting guidance, the results of operations for these businesses are reported as discontinued operations and excluded from all periods presented in the accompanying information provided below.

38

	Three Months Ended September 30,					Nine Months Ended September 30,
(in millions)	2013		2012			2013		2012
Product revenues	$	533.7	$	601.3		$	1,489.0	$	1,558.7
Service revenues	51.2		52.9			155.0		111.9
Total Other Business Operations revenues	584.9		654.2			1,644.0		1,670.6
Cost of Other Business Operations revenues	550.6		578.0			1,544.0		1,503.7
Other Business Operations gross profit	34.3		76.2			100.0		166.9
Other Business Operations SG&A expenses	22.1		97.1			63.4		190.3
Other Business Operations operating income (loss)	$	12.2	$	(20.9	)	$	36.6	$	(23.4	)
Claims
Home delivery and specialty	—		0.3			—		0.6
Total adjusted Other Business Operations claims(1)	—		0.9			—		1.8

(1) Total adjusted claims reflect home delivery claims multiplied by 3, as home delivery claims typically cover a time period 3 times longer than retail claims.

Other Business Operations Results of Operations: Other Business Operations operating income increased by $33.1 million for the three months ended September 30, 2013 from the same period of 2012. This increase is primarily due to losses incurred on businesses for the three months ended September 30, 2012 which were substantially shut down as of December 31, 2012, as well as impairment charges associated with our Liberty brand of $23.0 million, partially offset by a $14.3 million gain associated with the sale of ConnectYourCare (“CYC”) for the three months ended September 30, 2012.

Other Business Operations operating income increased by $60.0 million for the nine months ended September 30, 2013 from the same period of 2012. This increase is primarily due to the acquisition of Medco and inclusion of its results of operations for the three months ended March 31, 2013 and a $3.5 million gain associated with settlement of working capital balances for ConnectYourCare (“CYC”) that was included for the nine months ended September 30, 2013. Offsetting these increases during 2013 are losses incurred on businesses for the nine months ended September 30, 2012 which were substantially shut down as of December 31, 2012, as well as impairment charges associated with our Liberty brand of $23.0 million. These increases were partially offset by a $14.3 million gain associated with the sale of CYC for the nine months ended September 30, 2012.

OTHER (EXPENSE) INCOME

Net other expense decreased by $53.3 million in the three months ended September 30, 2013 as compared to the same period of 2012. This decrease is primarily due to the early repayment of ESI’s $1.0 billion aggregate principal amount of 6.250% senior notes due 2014 and the redemption of Medco’s $300.0 million aggregate principal amount of 6.125% senior notes due 2013, in addition to a $24.9 million contractual interest payment received from a client.

Net other expense decreased by $27.3 million in the nine months ended September 30, 2013 as compared to the same period of 2012. This decrease is primarily due to interest of debt acquired from and issued in connection with the Merger, reduced interest for the nine months ended September 30, 2013 due to the early redemption of ESI’s $1.0 billion aggregate principal amount of 6.250% senior notes due 2014, and by a $24.9 million contractual interest payment received from a client.In addition, this decrease was partially due to greater undistributed gains from our joint venture of $23.1 million for the nine months ended September 30, 2013 compared to $9.4 million for the nine months ended September 30, 2012. These net decreases are partially offset by $68.5 million of redemption costs and write-off of deferred financing fees incurred for early redemption of debt as discussed above for the nine months ended September 30, 2013.

PROVISION FOR INCOME TAXES

Our effective tax rate from continuing operations attributable to Express Scripts increased to 42.5% and decreased to 39.3% for the three and nine months ended September 30, 2013, respectively, as compared to 38.4% and 42.1% for the same periods in 2012 due to both recurring and discrete events.

We recognized discrete charges from continuing operations of $38.7 million and $29.7 million for the three and nine months ended September 30, 2013, respectively, as compared to discrete benefits of $1.3 million and discrete charges of $43.5 million for the same periods in 2012. Our 2013 discrete charges primarily relate to changes in our unrecognized tax benefits, the deferred tax implications of newly enacted state laws, and the deferred tax implications related to investments in certain

39

foreign subsidiaries that we expect to realize in the foreseeable future. Our 2012 net discrete charges primarily relate to contingencies related to prior year income tax return filings, changes in our unrecognized tax benefits, and the reversal of the deferred tax asset previously established for transaction-related costs that became nondeductible upon the consummation of the Merger.

Our discontinued operations for the nine months ended September 30, 2013 reflect a discrete benefit of $10.1 million.

As of September 30, 2013, the Company was evaluating the potential tax benefit related to the disposition of a business acquired in the Merger. Based on information currently available, our best estimate resulted in no amounts being recorded at September 30, 2013. However, pending the resolution of certain matters, such benefit may become realizable in the future.

Additionally, we believe that it is reasonably possible that our unrecognized tax benefits could significantly change within the next twelve months due to the anticipated conclusion of various examinations. An estimate of the range of the reasonably possible change in the next 12 months cannot be made.

NET LOSS FROM DISCONTINUED OPERATIONS, NET OF TAX

During 2012, we determined that portions of the UBC business, operations in Europe (“European Operations”), and the Europa Apotheek Venlo B.V. (“EAV”) business were not core to our future operations and committed to a plan to dispose of these businesses. During 2013, we entered into an agreement for the sale of our acute infusion therapies line of business, which was included within our PBM segment. As a result, these lines of business are classified as discontinued operations. In accordance with applicable accounting guidance, the results of operations for the three and nine months ended September 30, 2012 have been restated to reflect these operations as discontinued. As these businesses were acquired with the Merger, results of operations for the three months ended March 31, 2012 do not include these operations.

Net loss from discontinued operations, net of tax, decreased by $4.5 million and increased by $22.1 million for the three and nine months ended September 30, 2013, respectively, from the same periods of 2012. The decrease for the three months ended September 30, 2013 is a result of a total gain of $33.5 million recognized in connection with the sale of the remaining portions of our UBC business partially offset by a $32.9 million impairment on our acute infusion therapies line of business during the third quarter of 2013, as well as impairment charges associated with our EAV line of business of $11.5 million during the three months ended September 30, 2012, which was sold in the fourth quarter of 2012. The increase for the nine months ended September 30, 2013 is the result of a total gain of $51.8 million recognized in connection with the sale of the remaining portions of our UBC business, partially offset by a $32.9 million impairment on our acute infusion therapies line of business and charges recognized on our European Operations of $16.0 million, as well as impairment charges associated with our EAV line of business of $11.5 million during the nine months ended September 30, 2012, which was sold in the fourth quarter of 2012.

NET INCOME ATTRIBUTABLE TO NON-CONTROLLING INTEREST

Net income attributable to non-controlling interest represents the share of net income allocated to members in our consolidated affiliates. Increases in these amounts are primarily driven by increased profitability.

NET INCOME AND EARNINGS PER SHARE ATTRIBUTABLE TO EXPRESS SCRIPTS

Net income attributable to Express Scripts for the three and ninemonths ended September 30, 2013increased $35.3 million, or 9.0%, and $533.9 million, or 66.0%, respectively, over the same periods of 2012, due to the factors described above.

Basic and diluted earnings per share increased 10.4% and 10.6%, respectively, for the three months ended September 30, 2013 over the same period of 2012. For the nine months ended September 30, 2013, basic and diluted earnings per share increased 43.5% and 43.4%, respectively, over the same period of 2012. These increases are primarily due to increased operating income during 2013, partially offset by amortization of intangible assets and financing and commitment fees.

40

EBITDA FROM CONTINUING OPERATIONS ATTRIBUTABLE TO EXPRESS SCRIPTS

We have provided below a reconciliation of adjusted EBITDA from continuing operations attributable to Express Scripts to net income attributable to Express Scripts as we believe it is the most directly comparable measure calculated under accounting principles generally accepted in the United States:

EBITDA from continuing operations attributable to Express Scripts(1) (2)	Three Months Ended September 30,						Nine Months Ended September 30,
(in millions, except per claim data)	2013			2012			2013			2012
Net income attributable to Express Scripts	$	426.7		$	391.4		$	1,342.7		$	808.8
Less: Net loss from discontinued operations, net of tax	(15.5		)	(20.0		)	(41.3		)	(19.2		)
Net income from continuing operations attributable to Express Scripts	442.2			411.4			1,384.0			828.0
Provision for income taxes	326.5			256.1			896.0			602.5
Depreciation and amortization	614.3			610.5			1,824.0			1,270.0
Interest expense, net	101.7			153.8			442.0			455.6
Equity income from joint venture	(6.3		)	(5.1		)	(23.1		)	(9.4		)
EBITDA from continuing operations attributable to Express Scripts	1,478.4			1,426.7			4,522.9			3,146.7
Adjustments to EBITDA from continuing operations attributable to Express Scripts
Transaction and integration costs(3)	178.5			189.4			473.0			608.3
Adjusted EBITDA from continuing operations attributable to Express Scripts	1,656.9			1,616.1			4,995.9			3,755.0
Total adjusted claims from continuing operations	358.1			393.7			1,117.3			984.6
Adjusted EBITDA from continuing operations attributable to Express Scripts per adjusted claim(4)	$	4.63		$	4.10		$	4.47		$	3.81

(1) EBITDA from continuing operations attributable to Express Scripts is earnings before other income (expense), interest, taxes, depreciation and amortization, or alternatively calculated as operating income from continuing operations plus depreciation and amortization less non-controlling interest. EBITDA from continuing operations attributable to Express Scripts is presented because it is a widely accepted indicator of a company’s ability to service indebtedness and is frequently used to evaluate a company’s performance. EBITDA from continuing operations attributable to Express Scripts, however, should not be considered as an alternative to net income from continuing operations, as a measure of operating performance, as an alternative to cash flow, as a measure of liquidity or as a substitute for any other measure computed in accordance with accounting principles generally accepted in the United States. In addition, our definition and calculation of EBITDA from continuing operations attributable to Express Scripts may not be comparable to that used by other companies.

(2) During 2012 and 2013, we determined that various businesses acquired in the Merger were no longer core to our future operations and committed to a plan to dispose of these businesses. In accordance with applicable accounting guidance, the results of operations for these businesses are reported as discontinued operations for all periods presented in the accompanying financial information.

(3) Transaction and integration costs for the three and nine months ended September 30, 2013 presented above excludes $9.1 million and $11.1 million, respectively, of depreciation related to the integration of Medco which does not impact EBITDA.

(4) Adjusted EBITDA from continuing operations attributable to Express Scripts per adjusted claim is a supplemental measurement used by analysts and investors to help evaluate overall operating performance. We have calculated adjusted EBITDA from continuing operations attributable to Express Scripts excluding certain charges recorded each year, as these charges are not considered an indicator of ongoing company performance. Adjusted EBITDA from continuing operations attributable to Express Scripts per adjusted claim is calculated by dividing adjusted EBITDA from continuing operations attributable to Express Scripts by the adjusted claim volume for the period. This measure is used as an indicator of adjusted EBITDA from continuing operations attributable to Express Scripts performance on a per-unit basis. Adjusted EBITDA from continuing operations attributable to Express Scripts, and as a result, adjusted EBITDA from continuing operations attributable to Express Scripts per adjusted claim, are affected by the changes in claim volumes between retail and home delivery, the relative representation of brand-name, generic and specialty pharmacy drugs, as well as the level of efficiency in the business.

41

LIQUIDITY AND CAPITAL RESOURCES

OPERATING CASH FLOW, CAPITAL EXPENDITURES AND FINANCING

For the nine months ended September 30, 2013, net cash provided by continuing operations decreased$202.3 million compared to the same period of 2012 to $1,843.1 million. Changes in working capital resulted in a cash outflow of $1,169.7 million for the nine months ended September 30, 2013 compared to a cash outflow of $110.2 million over the same period of 2012, resulting in a total change of $1,059.5 million. The working capital decrease was primarily due to the timing and receipt of claims and rebates payable and accounts receivable. This decrease was partially offset by an increase in net income from continuing operations of $569.7 million in the nine months ended September 30, 2013 compared to the same period of 2012.

Net cash provided by investing activities by continuing operations was $12.1 million for the nine months ended September 30, 2013, compared to net cash used in investing activities by continuing operations of $10,412.6 million over the same period of 2012. This change is primarily attributable to $10,326.0 million of cash outflows associated with the Merger during 2012. Capital expenditures for purchases of property and equipment increased compared to the prior period due primarily to integration-related investments. We intend to continue to invest in infrastructure and technology that we believe will provide efficiencies in operations, facilitate growth and enhance the service we provide to our clients. Anticipated capital expenditures will be funded primarily from operating cash flow or, to the extent necessary, with borrowings under our revolving credit facility, discussed below. The proceeds from the sale of discontinued operations, as discussed in Note 4 - Dispositions, offset capital expenditures for the nine months ended September 30, 2013.

Net cash used in financing activities by continuing operations was $2,922.0 million for the nine months ended September 30, 2013, which represents a change of $6,868.7 million compared to the same period in 2012. Outflows in 2013 were primarily due to $1,300.0 million related to the redemption of senior notes, $473.7 million of quarterly term facility payments and treasury share repurchases of $1,552.5 million during the nine months ended September 30, 2013 compared to net outflows of $1,500.0 million related to the redemption of senior notes, outflows of $1,000.0 million related to redemption of the senior unsecured term loan, proceeds of $3,458.9 million from the issuance of senior notes and proceeds of $4,000.0 million in connection with the term facility used to fund the Merger which were received during the nine months ended September 30, 2012.

The Company is a provider to State of Illinois employees. As of September 30, 2013, the Company had an outstanding receivable balance of approximately $324.9 million. The Company has not recorded a reserve against this receivable, as it is associated with a State, which continues to make payments. The Company believes that the full receivable balance will be realized.

We anticipate that our current cash balances, cash flows from operations and our revolving credit facility will be sufficient to meet our cash needs and make scheduled payments for our contractual obligations and current capital commitments. However, if needs arise, we may decide to secure external capital to provide additional liquidity. New sources of liquidity may include additional lines of credit, term loans, or issuance of notes or common stock, all of which are allowable, with certain limitations, under our existing credit agreement and other debt instruments. While our ability to secure debt financing in the short term at rates favorable to us may be moderated due to various factors, including the financing incurred in connection with the Merger, market conditions or other factors, we believe our liquidity options discussed above should be sufficient to meet our anticipated cash flow needs.

42

CHANGES IN BUSINESS

As a result of the Merger on April 2, 2012, Medco and ESI each became 100% owned subsidiaries of the Company and former Medco and ESI stockholders became owners of Express Scripts stock, which is listed for trading on the Nasdaq. Upon closing of the Merger, former ESI stockholders owned approximately 59% of Express Scripts and former Medco stockholders owned approximately 41% of Express Scripts. Per the terms of the Merger Agreement, upon consummation of the Merger on April 2, 2012, each share of Medco common stock was converted into (i) the right to receive $28.80 in cash, without interest, and (ii) 0.81 shares of Express Scripts stock. Holders of Medco stock options, restricted stock units and deferred stock units received replacement awards at an exchange ratio of 1.3474 Express Scripts awards for each Medco award owned, which is equal to the sum of (i) 0.81 and (ii) the quotient obtained by dividing (1) $28.80 (the cash component of the Merger consideration) by (2) an amount equal to the average of the closing prices of ESI common stock on the Nasdaq for each of the 15 consecutive trading days ending with the fourth complete trading day prior to the completion of the Merger. Based on the opening price of Express Scripts’ stock on April 2, 2012, total consideration was $30.2 billion, composed of $11.3 billion in cash, $18.0 billion in common stock of the Company and $0.9 billion of replacement stock options and restricted stock units.

We regularly review potential acquisitions and affiliation opportunities. We believe available cash resources, bank financing or the issuance of additional common stock could be used to finance future acquisitions or affiliations. There can be no assurance we will make new acquisitions or establish new affiliations in the future.

STOCK REPURCHASE PROGRAM

On March 6, 2013, the Board of Directors of Express Scripts approved a new share repurchase program (the “2013 Share Repurchase Program”), authorizing the repurchase of up to 75.0 million shares (as adjusted for any subsequent stock split, stock dividend or similar transaction) of the Company’s common stock. There is no limit on the duration of the 2013 Share Repurchase Program.

During the three and nine months ended September 30, 2013, we repurchased 11.6 million and 24.9 million shares for $751.5 million and $1,552.5 million, respectively. Repurchases during the second quarter included 1.2 million shares of common stock for an aggregate purchase price of $68.4 million that were held on behalf of participants who acquired such shares upon the consummation of the Merger as a result of conversion of Medco shares previously held in Medco’s 401(k) plan. As previously announced, the Express Scripts 401(k) Plan no longer offers an investment fund option consisting solely of shares of Express Scripts common stock, and previously held shares were to be sold on or about the first anniversary of the Merger. This repurchase was not considered part of the 2013 Share Repurchase Program. The remaining shares repurchased throughout 2013 were purchased as part of the 2013 Share Repurchase Program. As of September 30, 2013, there were 51.3 million shares remaining under the 2013 Share Repurchase Program. Additional share repurchases, if any, will be made in such amounts and at such times as the Company deems appropriate based upon prevailing market and business conditions and other factors. Current year repurchases were funded through internally generated cash.

BANK CREDIT FACILITIES

On August 29, 2011, ESI entered into a credit agreement (the “credit agreement”) with a commercial bank syndicate providing for a five-year $4.0 billion term loan facility (the “term facility”) and a $1.5 billion revolving loan facility (the “revolving facility”). The term facility was used to pay a portion of the cash consideration in connection with the Merger (as discussed in Note 3 - Changes in business), to repay existing indebtedness and to pay related fees and expenses. Subsequent to consummation of the Merger on April 2, 2012, the revolving facility has been available for general corporate purposes. The term facility and the revolving facility both mature on August 29, 2016. As of September 30, 2013, no balance was outstanding under the revolving facility. The Company makes quarterly principal payments on the term facility. As of September 30, 2013, $631.6 million of this facility is considered current maturities of long-term debt. Upon consummation of the Merger, Express Scripts assumed the obligations of ESI and became the borrower under the credit agreement and revolving facility.

Our bank financing agreements contain covenants that restrict our ability to incur additional indebtedness, create or permit liens on assets and engage in mergers or consolidations. The covenants under the credit agreement exempt certain agreed upon actions taken in connection with the Merger. The covenants also include minimum interest coverage ratios and maximum leverage ratios. At September 30, 2013, we believe we were in compliance in all material respects with all covenants associated with our debt instruments (including the credit agreement and our senior notes).

See Note 7 - Financing for more information on our credit facilities.

43

SENIOR NOTES

On February 6, 2012, we issued $3.5 billion of Senior Notes, including:

• $1.0 billion aggregate principal amount of 2.100% Senior Notes due 2015

• $1.5 billion aggregate principal amount of 2.650% Senior Notes due 2017

• $1.0 billion aggregate principal amount of 3.900% Senior Notes due 2022

The net proceeds were used to pay a portion of the cash consideration paid in the Merger and to pay related fees and expenses (see Note 3 - Changes in business).

On November 14, 2011, we issued $4.1 billion of Senior Notes, including:

• $900 million aggregate principal amount of 2.750% Senior Notes due 2014

• $1.25 billion aggregate principal amount of 3.500% Senior Notes due 2016

• $1.25 billion aggregate principal amount of 4.750% Senior Notes due 2021

• $700 million aggregate principal amount of 6.125% Senior Notes due 2041

The net proceeds were used to pay a portion of the cash consideration paid in the Merger and to pay related fees and expenses (see Note 3 - Changes in business).

On May 2, 2011, ESI issued $1.5 billion aggregate principal amount of 3.125% Senior Notes due 2016. The proceeds were used to repurchase treasury shares.

On September 10, 2010, Medco issued $1.0 billion of Senior Notes, including:

• $500 million aggregate principal amount of 2.75% Senior Notes due 2015

• $500 million aggregate principal amount of 4.125% Senior notes due 2020

The net proceeds were used for general corporate purposes, including funding the UBC acquisition.

On June 9, 2009, ESI issued $2.5 billion of Senior Notes, including:

• $1.0 billion aggregate principal amount of 5.250% Senior Notes due 2012

• $1.0 billion aggregate principal amount of 6.250% Senior Notes due 2014

• $500 million aggregate principal amount of 7.250% Senior Notes due 2019

The net proceeds were used for the acquisition of WellPoint’s NextRx PBM Business. On June 15, 2012, the Company redeemed ESI’s $1.0 billion aggregate principal amount of 5.250% senior notes due 2012. On March 29, 2013, the Company redeemed ESI’s $1.0 billion aggregate principal amount of 6.250% senior notes due 2014. Each of the notes are redeemable at a redemption price equal to the greater of (i) 100% of the aggregate principal amount of the notes being redeemed, plus accrued and unpaid interest; or (ii) the sum of the present values of the remaining scheduled payments of principal and interest on the notes being redeemed, not including unpaid interest accrued to the redemption date, discounted to the redemption date on a semiannual basis at the treasury rate plus 50 basis points with respect to the notes being redeemed, plus unpaid interest of the notes being redeemed accrued to the redemption date. Total cash payments related to the redemption of the 6.250% senior notes due 2014 was $1.1 billion, which included $68.5 million of redemption costs and write-off of deferred financing fees, are reflected within the “interest expense and other” line item of the unaudited consolidated statement of operations for the nine months ended September 30, 2013 (see Note 7 - Financing for further discussion).

On March 18, 2008, Medco issued $1.5 billion of Senior Notes, including:

• $300.0 million aggregate principal amount of 6.125% Senior Notes due 2013

• $1.2 billion aggregate principal amount of 7.125% Senior Notes due 2018

The net proceeds were used to reduce debts under Medco’s revolving credit facility, which funded the PolyMedica Corporation and CCS Infusion Management, LLC acquisitions. On March 18, 2013, $300.0 million aggregate principal amount of 6.125% senior notes due 2013, issued by Medco, matured and were redeemed (see Note 7 - Financing for further discussion).

See Note 7 - Financing for more information on our Senior Notes borrowings.

44

OTHER MATTERS

In February 2013, the Financial Accounting Standards Board (“FASB”) issued authoritative guidance containing changes to the presentation of amounts reclassified out of accumulated other comprehensive income. This statement is effective for financial statements issued for annual periods beginning after December 15, 2012. Adoption of the standard impacts the presentation of certain information within the financial statements, but will not impact our financial position, results of operations or cash flows. The Company has not reclassified amounts out of accumulated other comprehensive income; and, as such, no additional information is presented for the three or nine months ended September 30, 2013 or 2012.

In July 2013, the FASB issued authoritative guidance containing changes to the presentation of an unrecognized tax benefit when a loss or credit carryforward exists. This statement is effective for financial statements issued for annual periods beginning after December 15, 2013, with early adoption permitted. Adoption of the standard is not expected to materially impact our financial position, results of operations, or cash flows.

IMPACT OF INFLATION

Changes in prices charged by manufacturers and wholesalers for pharmaceuticals affect our revenues and cost of revenues. Most of our contracts provide that we bill clients based on a generally recognized price index for pharmaceuticals.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

We are exposed to market risk from changes in interest rates related to debt outstanding under our credit agreement. Our earnings are subject to change as a result of movements in market interest rates. At September 30, 2013, we had $2,157.9 million of gross obligations, or $435.6 million net of cash, which were subject to variable rates of interest under our credit agreements. A hypothetical increase in interest rates of 1% would result in an increase in annual interest expense of approximately $4.4 million (pre-tax), presuming that obligations subject to variable interest rates remained constant.

Item 4. Controls and Procedures

We maintain a comprehensive set of disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (“Exchange Act”)) designed to provide reasonable assurance that information required to be disclosed in our filings under the Exchange Act is recorded, processed, summarized and reported accurately and within the time periods specified in the SEC’s rules and forms. Under the supervision and with the participation of our management, including our Chairman, President and Chief Executive Officer and our Vice President and Interim Chief Financial Officer, we have evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based upon this evaluation, the Chairman, President and Chief Executive Officer and the Vice President and Interim Chief Financial Officer concluded that the design and operation of these disclosure controls and procedures are effective in providing reasonable assurance of the achievement of the objectives described above.

On April 2, 2012, the Company acquired Medco Health Solutions, Inc. (“Medco”). As a result of the acquisition of Medco, the Company has incorporated internal controls over significant processes specific to the acquisition that it believes to be appropriate and necessary in consideration of the level of related integration. The Company plans to transition selected billing and adjudication processes to a consolidated platform throughout 2013. As the Company further integrates the Medco business, it will continue to review the internal controls and take further steps to ensure that the internal controls are effective and integrated appropriately.

On May 14, 2013, the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) issued an updated version of its Internal Control - Integrated Framework (“2013 Framework”). Originally issued in 1992 (“1992 Framework”), the framework helps organizations design, implement and evaluate the effectiveness of internal control concepts and simplify their use and application. The 1992 Framework will remain available during the transition period, which extends to December 15, 2014, after which time COSO will consider it as superseded by the 2013 Framework. As of September 30, 2013, the Company is utilizing the original framework published in 1992.

Except as described above, during the quarter ended September 30, 2013, there was no change in our internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

45

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

We and/or our subsidiaries are parties to a number of lawsuits, claims, government inquiries, investigations, charges and proceedings in which unspecified damages are sought. We cannot ascertain with any certainty at this time the monetary damages or injunctive relief that any of the opposing parties may seek to recover. We also cannot provide any assurance that the outcome of any of these matters, or some number of them in the aggregate, will not be materially adverse to our financial condition, consolidated results of operations, cash flows or business prospects. In addition, the expenses of defending these cases may have a material adverse effect on our financial results.

The following developments have occurred since the filing of our Quarterly Report on Form 10-Q for the three months ended June 30, 2013, relating to proceedings involving both legacy ESI and Medco:

• National Association of Chain Drug Stores, et al. v. Express Scripts, Inc. and Medco Health Solutions, Inc. (Case No. 2:05-mc-02025, United States District Court for the Western District of Pennsylvania). On March 29, 2012, two pharmacy trade groups and several retail pharmacies filed a lawsuit seeking a preliminary injunction to prohibit the merger between ESI and Medco. The Court held a hearing on plaintiffs' motion for preliminary injunction and ESI's motion to dismiss on April 10, 2012. On April 25, 2012, the Court denied plaintiffs' motion for preliminary injunction. On August 27, 2012, the Court granted ESI's motion to dismiss in part and denied it in part, allowing plaintiffs to re-file. On September 10, 2012, a pharmacy association, a specialty pharmacy and a pharmacy wholesaler filed an amended complaint alleging antitrust violations as a result of the merger between Express Scripts and Medco. On October 29, 2012, the Company filed a motion to dismiss Plaintiffs' amended allegations that the merger gave ESI and Medco monopsony power as purchasers of retail community pharmacy services in state markets. Plaintiffs filed opposition briefings on December 3, 2012. On June 28, 2013, the Court granted the Company's motion to dismiss and set a scheduling conference on August 12, 2013. On August 6, 2013, the remaining plaintiffs voluntarily dismissed their claims.

• United States of America ex. rel. Lucas W. Matheny and Deborah Loveland vs. Medco Health Solutions, Inc., et al.(Cause No. 08-14201-CIV-Graham/Lynch, United States District Court for the Southern District of Florida) (filed June 9, 2008). This is an unsealed, qui tam matter that relates to Medco's former subsidiary, PolyMedica Corporation and its subsidiaries, in which the government declined to intervene. The case is proceeding as a civil lawsuit, although the government could decide to intervene at any point during the course of the litigation. The complaint alleges that the PolyMedica companies violated the False Claims Act through their accounting practices of applying invoice payments to accounts receivable. On July 21, 2010, the United States District Court for the Southern District of Florida dismissed the action without prejudice. Relators filed an amended complaint that was dismissed with prejudice on October 22, 2010. Relators appealed the dismissal of two counts of the complaint and, on February 22, 2012, the Eleventh Circuit Court of Appeals reversed the dismissal and directed the United States District Court for the Southern District of Florida to reinstate those two claims. On December 3, 2012, Medco sold PolyMedica and its subsidiaries, including all its assets and liabilities, to FGST Investments, Inc. On February 15, 2013, ATLS Acquisition LLC, a holding company, and its PolyMedica subsidiaries, filed for Chapter 11 bankruptcy protection in cases styled In re ATLS Acquisition, et al. (United States Bankruptcy Court, District of Delaware, Case No. 13-10262). The bankruptcy action resulted in an automatic stay of this case as it relates to PolyMedica and its subsidiaries. On May 10, 2013, the United States Bankruptcy Court for the District of Delaware entered an Order extending the automatic stay of the bankruptcy protection to include non-debtor defendants Medco, Arlene Perazella and Carl Dolan. On May 14, 2013, the United States District Court for the Southern District of Florida entered an Order acknowledging the stay, closing the case for administrative purposes pending the bankruptcy action, and denying all motions as moot. On July 15, 2013, the United States Bankruptcy Court entered an Order requiring Relators to file proofs of claim by July 24, 2013, and setting Relators' claims for a bench trial in the bankruptcy action on November 4, 2013. On July 17, 2013, Relators appealed the bankruptcy court's Order to the United States District Court for the District of Delaware and filed a motion to stay the bankruptcy court's deadlines to file proofs of claim, as well as the bench trial, pending the appeal. On July 22, 2013, Relators filed a motion to withdraw their adversary proceeding in the bankruptcy court, requesting jurisdiction be placed in the United States District Court for either the District of Delaware or the Southern District of Florida. On August 2, 2013, the United States Bankruptcy Court for the District of Delaware denied Relators' motion to stay proceedings. On September 5, 2013, the PolyMedica entities filed a motion for summary judgment on Relators’ claims. A hearing on the dischargeability of Relators’ claims against the PolyMedica entities is scheduled in the bankruptcy action on November 4, 2013.

46

• United States ex rel. David Morgan v. Express Scripts, Inc. and Medco Health Solutions, Inc. et al. (Case No. 05-cv-1714 (HAA) (United States District Court for the District of New Jersey). This is an unsealed qui tam matter against ESI, Medco and other defendants. The government declined to intervene against defendants and the matter was unsealed on December 21, 2012. Morgan, the qui tam relator, served the Third Amended Complaint on the Company on January 3, 2013. Morgan alleges claims under the federal False Claims Act and the false claims acts of twenty-two states. The allegations asserted deal primarily with an alleged conspiracy among other defendants to inflate the published Average Wholesale Price (“AWP”) of certain drugs. Morgan generally alleges that ESI and Medco were aware of the alleged AWP inflation and submitted false claims to the government, or caused false claims to be submitted to the government, by failing to disclose the alleged AWP inflationto their government health care program customers in violation of an alleged fiduciary duty and/or in violation of alleged contractual obligations. Morgan also alleges that ESI and Medco failed to properly process and/or adjudicate claims for payment for prescription drugs dispensed to federal healthcare beneficiaries, which allegedly resulted in the submission to the government of false claims for payment. On April 16, 2013, ESI and Medco filed a motion to dismiss the complaint arguing that Morgan failed to plead his allegations with sufficient particularity to satisfy Federal Rules of Civil Procedure 9(b) and 12(b)(6), that he lacks standing to bring independent claims for breach of contract and fiduciary duty, and that Morgan is not an original source of the allegations because there has been prior public disclosure of his allegations. On September 7, 2013, Morgan filed an opposition to the Company’s motion to dismiss.

In addition to the foregoing matters, in the ordinary course of our business, there have arisen various legal proceedings, investigations or claims now pending against us or our subsidiaries. The effect of these actions on future financial results is not subject to reasonable estimation because the proceedings are in early stages and/or considerable uncertainty exists about the outcomes. Where insurance coverage is not available for such claims, or in our judgment, is not cost-effective, we maintain self-insurance accruals to reduce our exposure to future legal costs, settlements and judgments related to uninsured claims. Our self-insured accruals are based upon estimates of the aggregate liability for the costs of uninsured claims incurred and the retained portion of insured claims using certain actuarial assumptions followed in the insurance industry and our historical experience. It is not possible to predict with certainty the outcome of these claims, and we can give no assurance that any losses in excess of our insurance and any self-insurance accruals will not be material.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

The following is a summary of our stock repurchasing activity during the three months ended September 30, 2013 (share data in millions):

Period	Total number of shares purchased	Average price paid per share		Total number of shares purchased as part of a publicly announced program	Maximum number of shares that may yet be  purchased under the program
7/1/2013 - 7/31/2013	—	$	—	—	62.9
8/1/2013 - 8/31/2013	7.1	64.76		7.1	55.8
9/1/2013 - 9/30/2013	4.5	64.83		4.5	51.3
Third Quarter 2013 Total	11.6	$	64.78	11.6

The repurchases disclosed in this table were made pursuant to the share repurchase program announced on March 6, 2013 (the “2013 Share Repurchase Program”), which authorizes the repurchase of up to 75.0 million shares (as adjusted for any subsequent stock split, stock dividend or similar transaction) of the Company’s common stock. There is no limit on the duration of the 2013 Share Repurchase Program. Additional share repurchases, if any, will be made in such amounts and at such times as we deem appropriate based upon prevailing market and business conditions and other factors.

Item 6. Exhibits

(a) See Index to Exhibits below.

47

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

		EXPRESS SCRIPTS HOLDING COMPANY
		(Registrant)
Date:	October 24, 2013	By:	/s/ George Paz
			George Paz, Chairman, President and
			Chief Executive Officer
Date:	October 24, 2013	By:	/s/ Matthew Harper
			Matthew Harper, Vice President and
			Interim Chief Financial Officer

48

INDEX TO EXHIBITS

(Express Scripts Holding Company – Commission File Number 1-35490)

Exhibit Number	Exhibit
2.12	Stock and Interest Purchase Agreement among Express Scripts, Inc. and WellPoint, Inc., dated April 9, 2009, incorporated by reference to Exhibit No. 2.1 to Express Scripts, Inc.’s Current Report on Form 8-K filed April 14, 2009, File No. 000-20199.
2.22	Agreement and Plan of Merger, dated as of July 20, 2011, by and among Express Scripts, Inc., Medco Health Solutions, Inc., Aristotle Holding, Inc., Aristotle Merger Sub, Inc. and Plato Merger Sub, Inc., incorporated by reference to Exhibit 2.1 to Express Scripts, Inc.’s Current Report on Form 8-K filed July 22, 2011, File No. 000-20199.
2.3	Amendment No. 1 to Agreement and Plan of Merger, dated as of November 7, 2011, by and among Express Scripts, Inc., Medco Health Solutions, Inc., Aristotle Holding, Inc., Aristotle Merger Sub, Inc., and Plato Merger Sub, Inc., incorporated by reference to Exhibit 2.1 to Express Scripts, Inc.’s Current Report on Form 8-K filed November 8, 2011, File No. 000-20199.
3.1	Amended and Restated Certificate of Incorporation of the Company, incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed April 2, 2012.
3.2	Amended and Restated Bylaws of the Company, incorporated by reference to Exhibit 3.2 to the Company’s Current Report on Form 8-K filed April 2, 2012.
11.1	Statement regarding computation of earnings per share. (See Note 6 to the unaudited consolidated financial statements.)
31.11	Certification by George Paz, as Chairman, President and Chief Executive Officer of Express Scripts Holding Company, pursuant to Exchange Act Rule 13a-14(a).
31.21	Certification by Matthew Harper, as Vice President and Interim Chief Financial Officer of Express Scripts Holding Company, pursuant to Exchange Act Rule 13a-14(a).
32.11	Certification by George Paz, as Chairman, President and Chief Executive Officer of Express Scripts Holding Company, pursuant to 18 U.S.C. § 1350 and Exchange Act Rule 13a-14(b).
32.21	Certification by Matthew Harper, as Vice President and Interim Chief Financial Officer of Express Scripts Holding Company, pursuant to 18 U.S.C. § 1350 and Exchange Act Rule 13a-14(b).
101.11	XBRL Taxonomy Instance Document.
101.21	XBRL Taxonomy Extension Schema Document.
101.31	XBRL Taxonomy Extension Calculation Linkbase Document.
101.41	XBRL Taxonomy Extension Definition Linkbase Document.
101.51	XBRL Taxonomy Extension Label Linkbase Document.
101.61	XBRL Taxonomy Extension Presentation Linkbase Document.

49

1

Filed herein.

2

The Stock and Interest Purchase Agreement listed in Exhibit 2.1 and the Merger Agreement listed in Exhibit 2.2 (collectively, the “Agreements”) are not intended to modify or supplement any factual disclosures about the parties thereto, including the Company, and should not be relied upon as disclosure about such parties without consideration of the periodic and current reports and statements that the parties thereto file with the SEC. The terms of the Agreements govern the contractual rights and relationships, and allocate risks, among the parties in relation to the transactions contemplated by the Agreements. In particular, the representations and warranties made by the parties in the Agreements reflect negotiations between, and are solely for the benefit of, the parties thereto and may be limited or modified by a variety of factors, including: subsequent events, information included in public filings, disclosures made during negotiations, correspondence between the parties and disclosure schedules and disclosure letters, as applicable, to the Agreements. Accordingly, the representations and warranties may not describe the actual state of affairs at the date they were made or at any other time and you should not rely on them as statements of fact. In addition, the representations and warranties made by the parties in the Agreements may be subject to standards of materiality applicable to the contracting parties that differ from those applicable to investors. The schedules to the Agreements have been omitted pursuant to Item 601(b)(2) of Regulation S-K and will be furnished supplementally to the SEC upon request.

50